[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 524
11. Rivolta CM, Moya CM, Esperante SA, Gutnisky VJ, Varela V, Targovnik HM: [The thyroid as a model for molecular mechanisms in genetic diseases]. Medicina (B Aires); 2005;65(3):257-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The thyroid as a model for molecular mechanisms in genetic diseases].
  • [Transliterated title] La tiroides como modelo de mecanismos moleculares en enfermedades geneticas.
  • Thyroid diseases constitute a heterogeneous collection of abnormalities associated with mutations in genes responsible for the development of thyroid: thyroid transcription factor-1 (TTF-1), thyroid transcriptions factor-2 (TTF-2) and PAX8, or in one of the genes coding for the proteins involved in thyroid hormone biosynthesis such as thyroglobulin (TG), thyroperoxidase (TPO), hydrogen peroxide-generating system (DUOX2), sodium/iodide symporter (NIS), pendrin (PDS), TSH and TSH receptor (TSHr).
  • Somatic mutations of the TSHr have been identified in hyperfunctioning thyroid adenomas.
  • Another established thyroid disease is the resistance to thyroid hormone (RTH).
  • It is a syndrome of reduced tissue responsiveness to hormonal action caused by mutations located in the thyroid hormone receptor beta (TRbeta) gene.
  • In conclusion, the identification of mutations in the thyroid expression genes has provided important insights into structure-function relationships.
  • The thyroid constitutes an excellent model for the molecular study of genetic diseases.
  • [MeSH-minor] Humans. Iodide Peroxidase / genetics. Iodide Peroxidase / metabolism. Mutation. Receptors, Thyrotropin / genetics. Thyroid Hormones / biosynthesis. Thyroid Hormones / genetics

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16042141.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Receptors, Thyrotropin; 0 / Thyroid Hormones; EC 1.11.1.8 / Iodide Peroxidase
  • [Number-of-references] 106
  •  go-up   go-down


12. Magro G, Benkova K, Michal M: Meningioma-like tumor of the thyroid: a previously undescribed variant of follicular adenoma. Virchows Arch; 2005 Jun;446(6):677-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma-like tumor of the thyroid: a previously undescribed variant of follicular adenoma.
  • [MeSH-major] Adenoma / pathology. Meningioma / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Clin Path. 2000 Jan;4(1):35-9 [10936897.001]
  • [Cites] AMA Arch Pathol. 1954 Dec;58(6):554-63 [13217570.001]
  • [Cites] Endocr Pract. 2001 Sep-Oct;7(5):370-4 [11585373.001]
  • [Cites] Virchows Arch. 2005 Jan;446(1):91-2 [15517364.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):199-204 [11863215.001]
  • (PMID = 15891903.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Musholt PB, Musholt TJ, Morgenstern SC, Worm K, Sheu SY, Schmid KW: Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot. World J Surg; 2008 May;32(5):722-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
  • BACKGROUND: The BRAF V600E mutation is the most prevalent genetic aberration in papillary thyroid carcinomas (PTCs), and it is found exclusively in RET/PTC-negative tumors.
  • In oncocytic (Hürthle cell, oxyphilic) thyroid tumors, the presence of RET/PTC rearrangements is associated with either the conventional papillary histotype or the "solid" Hürthle cell tumors, whereas all predominantly follicular oncocytic carcinomas do not harbor RET/PTC chimeras.
  • Although 12% of tumors of the follicular variant of PTC carry BRAF mutations, none of the few oncocytic follicular thyroid adenomas (oncoAd) or carcinomas (oncoFTC) published worldwide tested positive.
  • An aspired molecular-based classification of oncocytic thyroid tumors is in need of additional evidence on BRAF mutations in the follicular histotype.
  • METHODS: A series of 44 oncocytic thyroid tumors with well-documented clinicopathological data was subjected to BRAF mutation analysis (complete exon 15) by automated sequencing.
  • RESULTS: The series of oncocytic thyroid tumors consisted of 21 adenomas (oncoAds: 17 females, 4 males; mean age, 54.5 years; range, 27-80 years), 20 follicular carcinomas (oncoFTCs: 14 females, 6 males; mean age, 61.4 years; range, 39-80 years), and 3 "classic" papillary carcinomas (oncoPTCs: 3 females; mean age, 58.1 years; range, 46-70 years; 3x T2 tumors).
  • The follicular variants of oncocytic cancers are divided into 11x T2, 5x T3, and 4x T4 tumor stages (International Union Against Cancer [UICC] TNM 5th edition).
  • CONCLUSIONS: Our results add to the evidence that, in contrast to follicular variants of oncoPTCs, predominantly follicular oncocytic thyroid tumors harbor neither RET/PTC rearrangements nor BRAF mutations.
  • Furthermore, the findings support the concept that oncocytic neoplasms of the thyroid gland are oncocytic counterparts of the respective histotype (adenoma, FTC, PTC, or poorly differentiated thyroid carcinoma) rather than a separate tumor entity.
  • Molecular characterization of oncocytic thyroid malignancies for RET/PTC or BRAF genetic alterations may help with (preoperative) classification and prognostic evaluation of these tumors.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenoma, Oxyphilic / genetics. Carcinoma, Papillary / genetics. Mutation. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Endocrinol (Oxf). 2004 Aug;61(2):239-43 [15272920.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):364-9 [11788677.001]
  • [Cites] Surgery. 2000 Dec;128(6):984-93 [11114633.001]
  • [Cites] Surgery. 2003 Dec;134(6):881-9; discussion 889 [14668719.001]
  • [Cites] Int J Surg Pathol. 2005 Jan;13(1):29-35 [15735852.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):694-7 [16021577.001]
  • [Cites] Endocr Relat Cancer. 2007 Jun;14(2):445-52 [17639057.001]
  • [Cites] Endocr J. 2007 Jun;54(3):399-405 [17429154.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4578-80 [12881714.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):38-46 [17520704.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):245-62 [15947100.001]
  • [Cites] J Surg Res. 2007 Dec;143(2):350-63 [17655865.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(5):816-21 [15763659.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Nov;63(5):588-93 [16268813.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):216-22 [16434896.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):878-82 [10690905.001]
  • [Cites] Endocrinology. 2006 Feb;147(2):1014-9 [16254036.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):196-200 [17044028.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] Endocrinology. 2004 Dec;145(12):5448-51 [15331579.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):455-64 [16728573.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 [14602780.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4561-7 [12907632.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Jan;64(1):105-9 [16402937.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):485-95 [16728576.001]
  • [Cites] Endocr Pathol. 2005 Summer;16(2):99-105 [16199894.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):385-93 [16506015.001]
  • [Cites] Virchows Arch. 2005 Jun;446(6):589-95 [15902486.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 May;66(5):678-83 [17381488.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):779-87 [17464312.001]
  • [Cites] Adv Anat Pathol. 2001 Nov;8(6):345-54 [11707626.001]
  • (PMID = 18235983.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


1
Advertisement
4. Eszlinger M, Paschke R: Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol Cell Endocrinol; 2010 Jun 30;322(1-2):29-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns.
  • Fine-needle aspiration biopsy (FNAB) is currently the most sensitive and specific tool for the presurgical differential diagnosis of thyroid malignancy, but has also substantial limitations.
  • While approximately 75% of FNAB reveal benign lesions and 5% already cytologically prove malignancy, up to 20% of FNAB show follicular proliferation for which follicular adenoma, follicular carcinoma, and follicular variant of papillary carcinoma can only be distinguished histologically, thus requiring thyroid surgery.
  • However, new biomarkers that might improve the accuracy of FNAB come along with the discovery of more and more details of the molecular etiology of thyroid tumors.
  • Nevertheless, the application of molecular markers will significantly improve thyroid tumor diagnosis and thus it will help to prevent unnecessary surgeries and it will also help to guide mutation-specific targeted therapies.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Carcinoma, Papillary / diagnosis. Thyroid Neoplasms / diagnosis. Thyroid Nodule / diagnosis. Thyroid Nodule / genetics
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biopsy, Fine-Needle. Diagnosis, Differential. Gene Expression Profiling. Humans. Mutation

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20083161.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 123
  •  go-up   go-down


15. Mofid AR, Yazdani T, Shahrzad M, Seyedalinaghi S, Zandieh S: Role of fine-needle aspiration in the management of thyroid nodules. Saudi Med J; 2009 Apr;30(4):515-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of fine-needle aspiration in the management of thyroid nodules.
  • OBJECTIVE: To show the benefits of fine-needle aspiration biopsy (FNAB) in managing thyroid nodules.
  • METHODS: As a retrospective study, reports of 888 FNABs of the thyroid performed during a period of 11 years (1996-2007) at Tehran University of Medical Sciences, Sina Hospital and Endocrine Clinic, Tehran, Iran were reviewed.
  • RESULTS: The cytology diagnoses by FNAB were: papillary 6 (3.2%); follicular neoplasm 51 (28%); follicular adenoma 10 (5.4%); Hurthle cell neoplasm 8 (4.3%); suspicious 20 (10.9%); inconclusive 2 (1%); and benign 85 (46.4%).
  • Due to surgery pathologic reports, malignant cytologies were: 6 (100%) for papillary, 1 (1.96%) for follicular neoplasm, 4 (50%) for Hurthle cell neoplasm.
  • CONCLUSION: Fine needle aspiration is a useful technique for selecting patients with nodular thyroid disease for surgery.
  • [MeSH-major] Goiter, Nodular / pathology. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19370278.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


16. Hegazy MA, Khater AA, Setit AE, Amin MA, Kotb SZ, El Shafei MA, Yousef TF, Hussein O, Shabana YK, Dayem OT: Minimally invasive video-assisted thyroidectomy for small follicular thyroid nodules. World J Surg; 2007 Sep;31(9):1743-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive video-assisted thyroidectomy for small follicular thyroid nodules.
  • Minimal access surgery in the thyroid compartment has evolved considerably over the past 10 years and now takes many forms.
  • This study examined the feasibility and reliability of minimally invasive thyroid surgery for the management of small benign thyroid lesions.
  • A total of 68 patients with small thyroid nodules admitted to the Oncology Center of Mansoura University, Egypt, were enrolled in this prospective randomized trial.
  • Exclusion criteria were nodules > 4 cm, presence of thyroiditis, and thyroid gland volume > 20 ml.
  • Preoperative diagnosis, operating time, blood loss, postoperative pain, complications, and cosmetic outcome were all evaluated.
  • The main preoperative pathology was a benign follicular lesion (70.5%), and the main postoperative final pathology was follicular adenoma (54.4%).
  • The two groups were comparable regarding age, sex, and extent of thyroid surgery.
  • [MeSH-major] Adenoma / surgery. Thyroid Nodule / surgery. Thyroidectomy / methods. Video-Assisted Surgery

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 2006 Oct;116(10):1745-8 [17003721.001]
  • [Cites] BMC Surg. 2005 Apr 27;5:9 [15857503.001]
  • [Cites] Langenbecks Arch Surg. 2000 Jul;385(4):261-4 [10958509.001]
  • [Cites] J Am Coll Surg. 2004 Aug;199(2):243-8 [15275880.001]
  • [Cites] Endocr Pract. 2001 Sep-Oct;7(5):352-7 [11585370.001]
  • [Cites] Surg Endosc. 2002 Dec;16(12 ):1741-5 [12140635.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] Laryngoscope. 2006 Mar;116(3):350-6 [16540887.001]
  • [Cites] Surgery. 2001 Dec;130(6):1039-43 [11742335.001]
  • [Cites] Am Surg. 2001 Sep;67(9):880-4 [11565769.001]
  • [Cites] Med J Aust. 1986 Oct 6;145(7):308-11 [3531785.001]
  • [Cites] Endocrinol Metab Clin North Am. 2000 Mar;29(1):187-203 [10732271.001]
  • [Cites] Surgery. 2001 Dec;130(6):941-6 [11742321.001]
  • [Cites] J Am Coll Surg. 2001 May;192(5):665-8 [11333106.001]
  • [Cites] J Clin Endocrinol Metab. 1955 Oct;15(10):1270-80 [13263417.001]
  • [Cites] Ann Surg. 1987 Dec;206(6):782-6 [3689014.001]
  • [Cites] Arch Surg. 2002 Mar;137(3):301-4; discussion 305 [11888453.001]
  • [Cites] World J Surg. 1996 Sep;20(7):841-7 [8678960.001]
  • [Cites] Nuklearmedizin. 2001 Oct;40(5):148-54 [11727627.001]
  • [Cites] Ann Acad Med Singapore. 1996 Sep;25(5):744-7 [8924020.001]
  • [Cites] Laryngoscope. 2005 Jun;115(6):1104-8 [15933531.001]
  • [Cites] Curr Opin Oncol. 2006 Jan;18(1):43-7 [16357563.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2000 Feb;10(1):1-4 [10872517.001]
  • [Cites] ANZ J Surg. 2002 Nov;72(11):777-80 [12437686.001]
  • (PMID = 17653588.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


17. Murakami S, Sakata H, Okubo K, Tsuji Y, Kayano H: Thyroid adenoma with extensive extracellular mucin deposition: report of a case. Surg Today; 2007;37(3):226-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid adenoma with extensive extracellular mucin deposition: report of a case.
  • A thyroid tumor with extensive extracellular mucin deposition is extremely rare.
  • We herein describe a case of a thyroid adenoma with prominent myxoid stroma.
  • Radiological examinations showed this mass to be a thyroid tumor with a cystic component.
  • [MeSH-major] Adenoma / pathology. Mucins / analysis. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for thyroid adenoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thyroid. 1997 Oct;7(5):725-31 [9349575.001]
  • [Cites] Acta Pathol Jpn. 1992 Feb;42(2):111-4 [1314005.001]
  • [Cites] Cancer. 1985 Dec 1;56(11):2647-50 [2996743.001]
  • [Cites] Histopathology. 1984 Sep;8(5):847-60 [6083973.001]
  • [Cites] Am J Surg Pathol. 1985 Sep;9(9):619-29 [2996373.001]
  • [Cites] Cancer. 1976 Sep;38(3):1323-5 [182353.001]
  • [Cites] J Clin Pathol. 1985 Mar;38(3):277-80 [3973051.001]
  • [Cites] Histopathology. 2003 May;42(5):514-6 [12713633.001]
  • [Cites] J Oral Pathol. 1986 Nov;15(10):518-9 [3104557.001]
  • [Cites] J Clin Pathol. 1996 Dec;49(12):1015-7 [9038743.001]
  • [Cites] Hum Pathol. 1995 Oct;26(10):1099-108 [7557943.001]
  • [Cites] Thyroid. 1999 Apr;9(4):401-4 [10319948.001]
  • [Cites] Jpn J Clin Oncol. 1984 Sep;14(3):417-24 [6482020.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):195-200 [3277907.001]
  • [Cites] Pathol Res Pract. 1993 Jun;189(5):608-12; discussion 612-5 [8397391.001]
  • [Cites] J Pathol. 1991 Jul;164(3):261-3 [1679843.001]
  • [Cites] Arch Anat Cytol Pathol. 1990;38(3):114-6 [2363591.001]
  • [Cites] Cancer. 1990 May 1;65(9):2020-7 [1695544.001]
  • [Cites] Am J Surg Pathol. 1984 Sep;8(9):705-8 [6383090.001]
  • [Cites] Histopathology. 1987 Mar;11(3):317-26 [3428884.001]
  • [Cites] J Clin Pathol. 1987 Aug;40(8):890-5 [3654988.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Oct;57(4):551-6 [12354139.001]
  • [Cites] Cancer. 1980 May 15;45(10):2564-7 [6247054.001]
  • [Cites] Arch Pathol Lab Med. 2000 Oct;124(10 ):1547-52 [11035596.001]
  • [Cites] Arch Pathol Lab Med. 1983 Feb;107(2):70-4 [6687422.001]
  • [Cites] Int J Gynecol Pathol. 1996 Apr;15(2):137-45 [8786203.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):698-701 [16021578.001]
  • [Cites] Cytopathology. 2000 Jun;11(3):185-90 [10877279.001]
  • [Cites] Acta Pathol Jpn. 1987 Jul;37(7):1157-64 [2821736.001]
  • [Cites] Cancer. 1977 Jan;39(1):210-4 [832236.001]
  • (PMID = 17342362.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Mucins
  • [Number-of-references] 32
  •  go-up   go-down


18. Takano T, Higashiyama T, Uruno T, Yamada H, Yoshida H, Miyauchi A: Preparation of thyroid tumor cells in aspiration biopsies for aspiration biopsy nucleic acid diagnosis. Head Neck; 2008 Aug;30(8):983-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preparation of thyroid tumor cells in aspiration biopsies for aspiration biopsy nucleic acid diagnosis.
  • BACKGROUND: The relative expression level of trefoil factor 3 (TFF3) mRNA to galectin-3 (LGALS3) mRNA (T/G ratio) is a useful marker to distinguish thyroid follicular carcinomas from adenomas.
  • However, because of the interference by the simultaneously aspirated peripheral blood cells or infiltrating lymphocytes, the precise measurement of the T/G ratio in aspirates is difficult.
  • METHODS: We tested 2 methods of selecting thyroid tumor cells and removing blood cells from the aspirates.
  • [MeSH-major] Galectin 3 / metabolism. Peptides / metabolism. RNA, Messenger / metabolism. Thyroid Gland / pathology
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Antigens, CD45 / metabolism. Biomarkers, Tumor / immunology. Biopsy, Fine-Needle. Cell Separation. Filtration / instrumentation. Humans. Immunomagnetic Separation. Polymerase Chain Reaction. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18302262.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / Peptides; 0 / RNA, Messenger; 0 / TFF3 protein, human; 0 / human epithelial antigen-125; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


19. Snarska J, Szajda SD, Knaś M, Mroczko B, Borzym-Kluczyk M, Kamiński F, Zwierz P, Zwierz K: [Usefulness of detecting cancer procoagulant activity and thyrotropic hormone concentration in the differentiation of tumor-like changes in the thyroid]. Wiad Lek; 2006;59(5-6):332-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Usefulness of detecting cancer procoagulant activity and thyrotropic hormone concentration in the differentiation of tumor-like changes in the thyroid].
  • Epidemiological studies have shown the increased incidence of malignant cancer of the thyroid gland observed in the last decade.
  • This increase is connected with the elevated number of benign tumor-like/tuberous changes in the thyroid gland.
  • The aim of our study was to evaluate the usefulness of detecting cancer procoagulant activity (CP) and thyrotropic hormone concentration (TSH) in the differentiation of tumor-like changes in the thyroid gland.
  • The study included 15 patients (12 women and 3 men) with adenoma glandulae thyreoideae or nodular changes in the character of struma nodosa hyperplastica and 12 patients (11 women and 1 man) with carcinoma glandulae thyreoideae.
  • The results of our study indicate that the determination of CP activity can be used in the differential diagnosis of tumor-like changes of the thyroid gland.
  • [MeSH-major] Biomarkers, Tumor / blood. Cysteine Endopeptidases / blood. Goiter, Nodular / diagnosis. Neoplasm Proteins / blood. Thyroid Neoplasms / diagnosis. Thyrotropin / blood
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / metabolism. Adolescent. Adult. Aged. Blood Coagulation Factors / metabolism. Carcinoma / diagnosis. Carcinoma / metabolism. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Thyroid Diseases / diagnosis. Thyroid Diseases / metabolism

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17017477.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Coagulation Factors; 0 / Neoplasm Proteins; 9002-71-5 / Thyrotropin; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.26 / cancer procoagulant
  •  go-up   go-down


20. Cardenas MG, Kini S, Wisgerhof M: Two patients with highly aggressive macrofollicular variant of papillary thyroid carcinoma. Thyroid; 2009 Apr;19(4):413-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two patients with highly aggressive macrofollicular variant of papillary thyroid carcinoma.
  • BACKGROUND: The macrofollicular variant of papillary thyroid carcinoma (MFV-PTC) is an unusual type of thyroid carcinoma with histological features that can be confused with nodular goiter or follicular adenoma.
  • SUMMARY: The first patient was a 59-year-old woman with an occipital mass diagnosed histologically as papillary thyroid carcinoma (PTC), follicular variant.
  • Ten years earlier a biopsy of a thyroid nodule had been negative for malignant cells.
  • Thyroidectomy showed a 3-cm nodule in the thyroid, diagnosed as MFV-PTC.
  • The second patient was an 81-year-old man with a history of right thyroid nodule treated by total thyroidectomy with a postoperative diagnosis of adenomatous goiter.
  • Three years later he developed a right shoulder mass, histologically diagnosed as follicular variant of PTC.
  • He died of metastatic thyroid cancer.
  • Although MFV-PTC usually has a good prognosis these cases highlight the importance of careful histopathological examination for MFV-PTC in thyroidectomy specimens that may appear to be seemingly benign nodular thyroid disease.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Bone Neoplasms / secondary. Carcinoma, Papillary / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Fatal Outcome. Female. Humans. Male. Middle Aged. Thyroid Nodule / diagnosis. Thyroid Nodule / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19355832.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Verhulst P, Devos P, Aubert S, Buob D, Cranshaw I, Do Cao C, Pattou F, Carnaille B, Wemeau JL, Leteurtre E: A score based on microscopic criteria proposed for analysis of papillary carcinoma of the thyroid. Virchows Arch; 2008 Mar;452(3):233-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A score based on microscopic criteria proposed for analysis of papillary carcinoma of the thyroid.
  • Morphologic examination is the gold standard for diagnosing papillary thyroid carcinoma (PTC).
  • This diagnosis, especially for the follicular variant, may be variable even among experts.
  • Our objective was to analyze the frequency of PTC microscopic criteria in a series of thyroid tumors including follicular adenoma (FA) and PTC to build a score which could constitute a novel way for microscopic analysis of such thyroid tumors.
  • [MeSH-major] Carcinoma, Papillary / pathology. Thyroid Gland / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Histocytochemistry. Humans. Male. Middle Aged. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):16-8 [11791591.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):425-36; discussion 436-7 [15319714.001]
  • [Cites] Endocr Pathol. 2006 Fall;17(3):213-23 [17308358.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):19-21 [11789725.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1336-40 [15371949.001]
  • [Cites] Histopathology. 2005 Oct;47(4):391-401 [16178894.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Jul;5(4):573-84 [16013975.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] Endocr Pathol. 2006 Fall;17(3):225-34 [17308359.001]
  • [Cites] Endocrinology. 2007 Mar;148(3):936-41 [16946010.001]
  • [Cites] J Clin Pathol. 2007 Mar;60(3):244-50 [16798933.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):143-50 [11789719.001]
  • [Cites] Virchows Arch. 2004 Apr;444(4):350-5 [14758551.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):216-22 [16434896.001]
  • [Cites] Ann Surg. 2006 Nov;244(5):799-804 [17060774.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6586-97 [15475448.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):541-6 [15529186.001]
  • [Cites] Int J Surg Pathol. 2000 Jul;8(3):181-183 [11493987.001]
  • [Cites] Endocr Pathol. 2002 Summer;13(2):131-4 [12165661.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3214-23 [15240595.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):984-8 [16831055.001]
  • [Cites] Hum Pathol. 2006 Jul;37(7):824-30 [16784981.001]
  • [Cites] Am J Clin Pathol. 2006 Nov;126(5):700-8 [17050067.001]
  • [Cites] Hum Pathol. 2003 Nov;34(11):1081-2 [14652806.001]
  • [Cites] Virchows Arch. 2007 Mar;450(3):249-60 [17252232.001]
  • [Cites] World J Surg. 2006 May;30(5):752-8 [16680590.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 [16219715.001]
  • [Cites] Am J Clin Pathol. 2002 Oct;118(4):602-3; author reply 605-6 [12375648.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):292-306 [16557281.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1508-14 [12409728.001]
  • [Cites] Histopathology. 2004 Nov;45(5):493-500 [15500653.001]
  • [Cites] Surgery. 2005 Dec;138(6):1050-6; discussion 1056-7 [16360390.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):625-7 [12697856.001]
  • [Cites] Ann Pathol. 2003 Feb;23(1):7-10 [12743495.001]
  • (PMID = 18239937.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Laco J, Ryska A: [The use of immunohistochemistry in the differential diagnosis of thyroid gland tumors with follicular growth pattern]. Cesk Patol; 2006 Jul;42(3):120-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The use of immunohistochemistry in the differential diagnosis of thyroid gland tumors with follicular growth pattern].
  • The aim of the study was to evaluate the expression of galectin-3 (gal3), cytokeratin 19 (CK19), neural cell adhesion molecule (NCAM), and E-cadherin (Ecad) in thyroid gland tumors with follicular growth pattern with particular focus on their use in differential diagnosis.
  • A series of 139 cases - 87 follicular adenomas (FAs), 26 follicular carcinomas (FCs), and 26 cases of the follicular variant of papillary carcinoma (FVPC) was studied.
  • Therefore, the use of gal3 and CK19 in differential diagnosis of FVPC versus FA and FC can be recommended.
  • [MeSH-major] Biomarkers, Tumor / analysis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenoma / chemistry. Adenoma / diagnosis. Adolescent. Adult. Aged. Aged, 80 and over. Cadherins / analysis. Carcinoma, Papillary / chemistry. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary, Follicular / chemistry. Carcinoma, Papillary, Follicular / diagnosis. Diagnosis, Differential. Female. Galectin 3 / analysis. Humans. Immunohistochemistry. Keratins / analysis. Male. Middle Aged. Neural Cell Adhesion Molecule L1 / analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16955558.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Galectin 3; 0 / Neural Cell Adhesion Molecule L1; 68238-35-7 / Keratins
  •  go-up   go-down


23. Hindié E, Ugur O, Fuster D, O'Doherty M, Grassetto G, Ureña P, Kettle A, Gulec SA, Pons F, Rubello D, Parathyroid Task Group of the EANM: 2009 EANM parathyroid guidelines. Eur J Nucl Med Mol Imaging; 2009 Jul;36(7):1201-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary hyperparathyroidism is an endocrine disorder with high prevalence, typically caused by a solitary parathyroid adenoma, less frequently (about 15%) by multiple parathyroid gland disease (MGD) and rarely (1%) by parathyroid carcinoma.
  • Patients with MGD may have a double adenoma or hyperplasia of three or all four parathyroid glands.
  • Scintigraphy should also report on thyroid nodules that may cause confusion with a parathyroid adenoma or require concurrent surgical resection.
  • [MeSH-minor] Humans. Hyperparathyroidism / diagnosis. Hyperparathyroidism / pathology. Hyperparathyroidism / physiopathology. Hyperparathyroidism / surgery. Image Processing, Computer-Assisted. Iodine Radioisotopes / pharmacokinetics. Radiometry. Sodium Pertechnetate Tc 99m / pharmacokinetics. Subtraction Technique. Technetium Tc 99m Sestamibi / pharmacokinetics. Tissue Distribution. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2009 Feb;94(2):335-9 [19193908.001]
  • [Cites] Radiology. 2000 Feb;214(2):393-402 [10671586.001]
  • [Cites] PET Clin. 2007 Jul;2(3):385-93 [27158018.001]
  • [Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1251-62 [18684024.001]
  • [Cites] J Nucl Med. 1998 Jun;39(6):1111-4 [9627355.001]
  • [Cites] Am J Surg. 1996 Dec;172(6):633-6 [8988665.001]
  • [Cites] Head Neck. 2008 Apr;30(4):509-17 [18059012.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):467-73 [16404597.001]
  • [Cites] Lancet. 1997 Apr 26;349(9060):1233-8 [9130957.001]
  • [Cites] Eur J Nucl Med. 2000 Sep;27(9):1300-4 [11007510.001]
  • [Cites] J Nucl Med. 2007 Jul;48(7):1084-9 [17574983.001]
  • [Cites] Surgery. 2006 Nov;140(5):837-8 [17084734.001]
  • [Cites] Eur J Nucl Med. 1995 Jun;22(6):556-8 [7556303.001]
  • [Cites] Nucl Med Commun. 2003 Feb;24(2):133-40 [12548037.001]
  • [Cites] J Nucl Med. 1998 Oct;39(10):15N, 24N [9776261.001]
  • [Cites] Endocr Pract. 2005 Jan-Feb;11(1):49-54 [16033736.001]
  • [Cites] J Nucl Med. 1992 Oct;33(10 ):1801-7 [1328564.001]
  • [Cites] Surgery. 1997 Mar;121(3):287-94 [9092129.001]
  • [Cites] J Nucl Med. 1992 Mar;33(3):313-8 [1531500.001]
  • [Cites] Panminerva Med. 2002 Jun;44(2):99-105 [12032427.001]
  • [Cites] Nephrol Dial Transplant. 1997 Jan;12 (1):97-100 [9027781.001]
  • [Cites] J Nucl Med. 2003 Sep;44(9):1443-58 [12960191.001]
  • [Cites] Radiology. 2001 Mar;218(3):916-7 [11230677.001]
  • [Cites] J Nucl Med. 1998 Jun;39(6):1100-5 [9627353.001]
  • [Cites] J Nucl Med. 1997 Jun;38(6):831-4 [9189124.001]
  • [Cites] Surgery. 1993 Dec;114(6):1011-8 [8256204.001]
  • [Cites] Nucl Med Commun. 2006 Dec;27(12):977-87 [17088684.001]
  • [Cites] Radiology. 1997 Jul;204(1):221-8 [9205251.001]
  • [Cites] J Nucl Med. 1996 Nov;37(11):1809-15 [8917180.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jan;81(1):346-52 [8550776.001]
  • [Cites] Semin Ultrasound CT MR. 1995 Aug;16(4):279-95 [7576775.001]
  • [Cites] Lancet. 1999 Jun 26;353(9171):2200-4 [10392985.001]
  • [Cites] Surgery. 1986 Jun;99(6):643-51 [3715716.001]
  • [Cites] Nucl Med Commun. 1989 Nov;10 (11):791-4 [2532313.001]
  • [Cites] J Nucl Med. 2005 Feb;46(2):248-52 [15695783.001]
  • [Cites] Clin Med Res. 2004 Feb;2(1):55-8 [15931335.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1024-9 [11889156.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 May;34(5):796-8 [17406866.001]
  • [Cites] Am Surg. 2003 Aug;69(8):720-5 [12953832.001]
  • [Cites] Ann Intern Med. 1991 Apr 1;114(7):593-7 [1900404.001]
  • [Cites] Minerva Endocrinol. 2008 Jun;33(2):95-104 [18268473.001]
  • [Cites] Surgery. 1984 Jan;95(1):14-21 [6691181.001]
  • [Cites] Arch Surg. 2002 Sep;137(9):1055-9 [12215160.001]
  • [Cites] Arch Surg. 2000 Dec;135(12 ):1461-8 [11115353.001]
  • [Cites] World J Surg. 2008 May;32(5):774-81; discussion 782-3 [18335276.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):453-9 [16435115.001]
  • [Cites] Am J Kidney Dis. 2008 Sep;52(3):519-30 [18514987.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Mar;35(3):637-43 [17960377.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Feb;134(2):316-20 [16455383.001]
  • [Cites] Arch Surg. 2002 Aug;137(8):917-22; discussion 922-3 [12146990.001]
  • [Cites] Nucl Med Commun. 2004 Nov;25(11):1089-93 [15577586.001]
  • [Cites] J Nucl Med. 2004 Jan;45(1):40-8 [14734671.001]
  • [Cites] J Nucl Med. 2008 Dec;49(12):2012-7 [18997051.001]
  • [Cites] Eur J Endocrinol. 1998 Aug;139(2):195-7 [9724076.001]
  • [Cites] Environ Health Perspect. 1997 Dec;105 Suppl 6:1403-9 [9467052.001]
  • [Cites] Surgery. 1997 Dec;122(6):998-1003; discussion 1003-4 [9426412.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):189-2 [12643287.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Aug;57(2):241-9 [12153604.001]
  • [Cites] J Nucl Med. 1996 Nov;37(11):1773-8 [8917173.001]
  • [Cites] Eur J Nucl Med. 1994 Jan;21(1):17-22 [8088281.001]
  • [Cites] Surgery. 1999 Dec;126(6):1023-8; discussion 1028-9 [10598183.001]
  • [Cites] J Nucl Med. 2006 Jul;47(7):1227-34 [16818960.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jan;80(1):302-7 [7829631.001]
  • [Cites] J Am Coll Surg. 2002 Jul;195(1):19-22 [12113540.001]
  • [Cites] Radiology. 1994 Jul;192(1):280 [8208955.001]
  • [Cites] Clin Nucl Med. 2000 Jul;25(7):527-31 [10885694.001]
  • [Cites] World J Surg. 2006 Jan;30(1):76-83 [16369710.001]
  • [Cites] Br J Surg. 1982 May;69(5):244-7 [7074331.001]
  • [Cites] Arch Surg. 1989 Aug;124(8):911-4; discussion 914-5 [2757503.001]
  • [Cites] J Bone Miner Res. 2002 Nov;17 Suppl 2:N37-43 [12412776.001]
  • [Cites] Arch Surg. 2002 Aug;137(8):967-70 [12147000.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):989-91 [8813796.001]
  • [Cites] Ann Surg Oncol. 2008 Oct;15(10):2653-60 [18677536.001]
  • [Cites] J Nucl Med. 2003 Jun;44(6):904-8 [12791817.001]
  • [Cites] Eur J Nucl Med. 2001 Sep;28(9):1409-20 [11585302.001]
  • [Cites] Radiology. 1998 Apr;207 (1):207-13 [9580138.001]
  • [Cites] Adv Anat Pathol. 2005 Mar;12(2):53-61 [15731573.001]
  • [Cites] J Nucl Med. 1991 Aug;32(8):1627-39 [1869992.001]
  • [Cites] Nucl Med Commun. 1995 Jul;16(7):522-33 [7478389.001]
  • [Cites] Eur J Endocrinol. 2003 Jul;149(1):7-15 [12824860.001]
  • [Cites] J Nucl Med. 1983 May;24(5):438-41 [6842292.001]
  • [Cites] Radiology. 1996 Oct;201(1):85-91 [8816526.001]
  • [Cites] Minerva Endocrinol. 2001 Mar;26(1):3-12 [11323562.001]
  • [Cites] J Nucl Med Technol. 2007 Sep;35(3):135-9 [17702904.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Nov;83(11):3867-71 [9814460.001]
  • [Cites] Eur J Nucl Med. 1996 Jun;23 (6):693-6 [8662105.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12 ):1235-9 [18086965.001]
  • (PMID = 19471928.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 971Z4W1S09 / Technetium Tc 99m Sestamibi; A0730CX801 / Sodium Pertechnetate Tc 99m
  •  go-up   go-down


24. Sherman JF, Leiman G, Naud S, Nathan MH, Ambaye AB: Follicular and Hürthle cell lesions of the thyroid: can inconclusive results be minimized? Acta Cytol; 2008 Nov-Dec;52(6):659-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular and Hürthle cell lesions of the thyroid: can inconclusive results be minimized?
  • OBJECTIVE: To assess the cytologic criteria for distinguishing neoplastic from nonneoplastic follicular cell and Hürthle cell thyroid lesions.
  • STUDY DESIGN: Ten previously described and commonly used cytologic criteria were evaluated and graded on a 0-4 scale in a consecutive series of thyroid fine needle aspirations (FNAs) reported as follicular or Hürthle cell neoplasms or lesions.
  • RESULTS: A total of 93 (57fo llicular cell and 36 Hühle cell) cases was analyzed.
  • No individual cytologic feature was helpful in distinguishing benign neoplarms from malignancy in either category (p > 0.05), but 4 or more coexistent cytologic features in combination were identified in 50.0% of follicular neoplasms, 13.6% of Hürthle cell neoplasms and none of the nonneoplastic lesions.
  • An unexpected number (13 of 93, 14.0%) of unrecognized papillary carcinomas, some of follicular subtype, was encountered.
  • CONCLUSION: In this series, the indeterminate thyroid FNA category could have been reduced by diagnosis of samples with 4 or more of the studied criteria as definite follicular (50% of cases) or Hürthle cell (13.6% of cases) neoplasms and by more astute recognition of papillary carcinomas (14.0% of cases), which blend into this category, often as a result of less-than-optimal sampling or preservation.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma, Oxyphilic / pathology. Carcinoma, Papillary / pathology. Thyroid Gland / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068668.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30CA22435
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


25. Puepet FH, Agaba EI, Chuhwak EK, Ugoya SO: Primary hyperparathyroidism presenting with severe hypertension in a middle aged Nigerian--a case report. Niger Postgrad Med J; 2008 Mar;15(1):58-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A parathyroid MIBI scan study showed an extensive area of significance towards the inferior pole of the right lobe of thyroid medially with a second area of very low significance medial to the left pole.
  • These findings indicated the presence of a right inferior parathyroid adenoma.
  • He had parathyroid surgery and a large adenoma in the right inferior gland and a smaller left inferior gland were removed and confirmed histologically.
  • [MeSH-major] Hyperparathyroidism, Primary / diagnosis. Hyperparathyroidism, Primary / etiology. Hypertension / complications
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / surgery. Antihypertensive Agents / therapeutic use. Humans. Lisinopril / therapeutic use. Male. Middle Aged. Nigeria. Osteoarthritis, Knee / complications. Parathyroid Neoplasms / diagnosis. Parathyroid Neoplasms / surgery. Parathyroidectomy

  • Genetic Alliance. consumer health - Hyperparathyroidism, primary.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • Hazardous Substances Data Bank. LISINOPRIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18408787.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Antihypertensive Agents; E7199S1YWR / Lisinopril
  •  go-up   go-down


26. Blankenship DR, Chin E, Terris DJ: Contemporary management of thyroid cancer. Am J Otolaryngol; 2005 Jul-Aug;26(4):249-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contemporary management of thyroid cancer.
  • Thyroid cancer is a relatively common and frequently curable malignant neoplasm, accounting for nearly 2% of all new cancers diagnosed annually in the United States.
  • We sought to review the epidemiology and pathology of the several types of thyroid cancer and to present our evidence-based management algorithm.
  • In addition to reviewing well-established approaches to diagnosis and management, emphasis is placed on newer techniques, including minimally invasive thyroidectomy, molecular detection of disease propensity, and the use of recombinant thyrotropin prior to radioiodine ablation.
  • [MeSH-major] Thyroid Neoplasms
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / therapy. Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / therapy. Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / therapy. Biopsy, Fine-Needle. Carcinoma / diagnosis. Carcinoma / pathology. Carcinoma / therapy. Carcinoma, Medullary / diagnosis. Carcinoma, Medullary / pathology. Carcinoma, Medullary / therapy. Evidence-Based Medicine. Humans. Lymphoma / diagnosis. Lymphoma / pathology. Lymphoma / therapy. Thyroid Gland / anatomy & histology. Thyroid Gland / embryology. Thyroid Gland / radionuclide imaging. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991091.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 90
  •  go-up   go-down


27. Ge Y, Luna MA, Cowan DF, Truong LD, Ayala AG: Thyrolipoma and thyrolipomatosis: 5 case reports and historical review of the literature. Ann Diagn Pathol; 2009 Dec;13(6):384-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because thyrolipoma (adenolipoma of thyroid) and thyrolipomatosis (diffuse lipomatosis of thyroid) are distinctively rare conditions with only few cases reported in the literature, we are reporting 5 additional cases.
  • All the 5 patients were adult females, with ages from 38 to 79 years, who presented with thyroid masses.
  • Four of the patients had normal thyroid function tests and one had mild hypothyroidism.
  • The thyroid specimens showed either circumscribed yellow-tan masses (cases 1, 2, and 3) or diffuse yellow-brown discoloration (cases 4 and 5).
  • Histologic examination revealed abundant mature fat infiltrating the affected thyroid tissue in 3 distinct patterns:.
  • (1) fat infiltration limited to follicular adenomas (thyrolipoma);.
  • (2) fat diffusely infiltrating throughout the thyroid gland (thyrolipomatosis); or (3) fat infiltration involving both follicular adenoma and their surrounding thyroid tissue.
  • Because of the rarity of thyroid fat-containing lesions, confusion in differential diagnosis may occasionally occur.
  • In addition, a papillary thyroid carcinoma was also identified in one case of thyrolipomatosis.
  • [MeSH-major] Lipoma / pathology. Lipomatosis / pathology. Thyroid Diseases / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Middle Aged. Thyroid Function Tests. Thyroidectomy. Thyroxine / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917474.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q51BO43MG4 / Thyroxine
  • [Number-of-references] 19
  •  go-up   go-down


28. Matesa N, Samija I, Kusić Z: Galectin-3 and CD44v6 positivity by RT-PCR method in fine needle aspirates of benign thyroid lesions. Cytopathology; 2007 Apr;18(2):112-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 and CD44v6 positivity by RT-PCR method in fine needle aspirates of benign thyroid lesions.
  • OBJECTIVE: To investigate whether the presence of macrophages and Hürthle cells (HC) in benign thyroid lesions could explain the false-positive expression of galectin-3 and CD44v6 detected by reverse transcriptase-polymerase chain reaction (RT-PCR).
  • METHODS: For galectin-3 and CD44v6, RT-PCR was performed on RNA isolated from aspirates obtained by ultrasound guided fine needle aspiration cytology (FNAC) from 123 patients with benign thyroid lesions.
  • The results of RT-PCR analysis were evaluated against the definitive FNAC diagnosis.
  • RESULTS: Galectin-3 expression was found in 29% follicular adenoma (FA), 26% Hashimoto thyroiditis (HT), and in 24% nodular goitre (NG).
  • [MeSH-major] Antigens, CD44 / metabolism. Biomarkers / metabolism. Biopsy, Fine-Needle. Cell Adhesion. Galectin 3 / metabolism. Glycoproteins / metabolism. Thyroid Diseases / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. False Positive Reactions. Goiter, Nodular / metabolism. Goiter, Nodular / pathology. Hashimoto Disease / metabolism. Hashimoto Disease / pathology. Humans. Macrophages / metabolism. Macrophages / pathology. Oxyphil Cells / metabolism. Oxyphil Cells / pathology. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17397496.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers; 0 / CD44v6 antigen; 0 / Galectin 3; 0 / Glycoproteins; 0 / RNA, Messenger
  •  go-up   go-down


29. Anderson CE, Graham C, Herriot MM, Kamel HM, Salter DM: CD98 expression is decreased in papillary carcinoma of the thyroid and Hashimoto's thyroiditis. Histopathology; 2009 Dec;55(6):683-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD98 expression is decreased in papillary carcinoma of the thyroid and Hashimoto's thyroiditis.
  • AIMS: CD98 is a component of the large neutral amino acid transporter (LAT), which is a cell surface amino acid transporter.
  • CD98 expression is increased in a variety of carcinomas but its distribution in the normal and neoplastic thyroid gland has not been reported.
  • The aim was to examine the immunohistochemical expression of CD98 in normal and diseased thyroid tissue.
  • METHODS AND RESULTS: One hundred and forty thyroid cases were selected from the archives of the Department of Pathology, including normal controls, neoplasms (follicular adenoma, follicular carcinoma and papillary carcinoma) and non-neoplastic conditions (multinodular goitre, Graves' disease and Hashimoto's thyroiditis).
  • In normal thyroid, there was moderately strong expression of CD98 in the lateral cell membranes of follicular cells.
  • A similar pattern of expression was seen in follicular adenoma, minimally invasive follicular carcinoma, multinodular goitre and Graves' disease.
  • CONCLUSIONS: CD98 expression is down-regulated in thyroid papillary carcinoma; this may relate to the better prognosis associated with many of these tumours.
  • [MeSH-major] Antigens, CD98 / metabolism. Carcinoma, Papillary / metabolism. Hashimoto Disease / metabolism. Thyroid Gland / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenoma / metabolism. Down-Regulation. Graves Disease / metabolism. Humans. Immunohistochemistry. Prognosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19922591.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD98
  •  go-up   go-down


30. Aiad H, Abdou A, Bashandy M, Said A, Ezz-Elarab S, Zahran A: Computerized nuclear morphometry in the diagnosis of thyroid lesions with predominant follicular pattern. Ecancermedicalscience; 2009;3:146
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computerized nuclear morphometry in the diagnosis of thyroid lesions with predominant follicular pattern.
  • BACKGROUND: Differential diagnosis of thyroid lesions with predominantly follicular pattern is one of the most common problems in thyroid pathology.
  • Development of more objective and reproducible tools for diagnosis is needed.
  • This work is aimed at studying the role of nuclear morphometry in differential diagnosis of different thyroid lesions having predominant follicular pattern.
  • MATERIAL AND METHODS: Semiautomatic image analysis system was used to measure a total of 8 nuclear parameters in 48 thyroid lesions including seven nodular goiter (NG), 14 follicular adenoma (FA), 14 follicular carcinoma (FC) and 13 follicular variant papillary carcinoma (FVPC).
  • CONCLUSION: Nuclear morphometric parameters may help in the differentiation between neoplastic and non-neoplastic thyroid lesions and between FVPC and follicular neoplasms (FC and FA) but they have no value in the differentiation between FC and FA.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22276011.001).
  • [ISSN] 1754-6605
  • [Journal-full-title] Ecancermedicalscience
  • [ISO-abbreviation] Ecancermedicalscience
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3224013
  • [Keywords] NOTNLM ; Thyroid / differential diagnosis / nuclear morphometry
  •  go-up   go-down


31. Haghpanah V, Shooshtarizadeh P, Heshmat R, Larijani B, Tavangar SM: Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma. Appl Immunohistochem Mol Morphol; 2006 Dec;14(4):422-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma.
  • This retrospective study of thyroid histologic samples aimed to assess the clinical usefulness of survivin immunostaining for discrimination between follicular adenoma and carcinoma of thyroid.
  • Immunohistochemical staining for survivin was performed on 41 lesions from patients who had undergone surgery for either follicular adenoma or carcinoma of thyroid.
  • Survivin expression was significantly (P < 0.005) higher in the cases that received a diagnosis of carcinoma in comparison with follicular adenomas cases.
  • Odds ratio of follicular carcinoma for survivin expression was 21.375 (95% CI: 3.283 to 139.177).
  • Our results showed potential value of survivin in discrimination between follicular thyroid adenoma and follicular thyroid carcinoma.
  • We conclude that survivin is a potential candidate for further investigation in the proper histologic diagnosis of thyroid cancers.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122639.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


32. Ito Y, Miyauchi A: Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid. Endocr J; 2009;56(2):177-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid.
  • Differentiated thyroid carcinoma originates from thyroid follicular cells and is the most prominent malignancy of the endocrine organs.
  • There are two histological types of differentiated carcinoma, namely, papillary and follicular carcinoma.
  • According to reports from Western countries, papillary carcinoma comprises 85.3% of thyroid malignancies in whites, and 72.3% in blacks.
  • In Japan, a previous study showed that the prevalence of papillary carcinoma was 78.4% based on material registered between 1977 and 1986, but according to recent findings reported in 2004 by Japanese Society of Thyroid Surgeons (JSTS), papillary carcinoma accounted for as much as 93% of all thyroid carcinomas.
  • Papillary carcinoma frequently metastasizes to the regional lymph node and shows multicentricity in the thyroid gland.
  • Follicular carcinoma accounts for 10.9-20.5% of the patients in the United States.
  • In Japan, the prevalence of follicular carcinoma was reported to be 17.2%, but it decreased to 5% in a report by JSTS in 2004.
  • This carcinoma is only occasionally diagnosed preoperatively, because it is hard to discriminate follicular carcinoma from benign adenoma on imaging studies and cytologic findings.
  • In contrast to papillary carcinoma, follicular carcinoma more often metastasizes to distant organs than regional lymph nodes.
  • In Japan, the prevalence of papillary carcinoma increased and that of follicular carcinoma decreased between reports from 1977 to 1986 and that in 2004, which may be because follicular variant of papillary carcinoma was classified into follicular carcinoma in the previous results.
  • Indeed, it is most important for physicians to correctly distinguish high-risk cases from those with an indolent character, although how to evaluate the biological characteristics of thyroid carcinoma and how to identify high-risk cases remains highly controversial.
  • In this review, the methods of distinguishing high-risk cases and the appropriate therapeutic strategies for papillary and follicular carcinomas predominantly based on our experience are emphasized and our proposals for therapies including surgical treatment are demonstrated.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / therapy. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / pathology. Humans. Japan / epidemiology. Lymphatic Metastasis / pathology. Prognosis. Thyroidectomy / methods

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18703852.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 113
  •  go-up   go-down


33. Matsuo SE, Fiore AP, Siguematu SM, Ebina KN, Friguglietti CU, Ferro MC, Kulcsar MA, Kimura ET: Expression of SMAD proteins, TGF-beta/activin signaling mediators, in human thyroid tissues. Arq Bras Endocrinol Metabol; 2010 Jun;54(4):406-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of SMAD proteins, TGF-beta/activin signaling mediators, in human thyroid tissues.
  • OBJECTIVE: To investigate the expression of SMAD proteins in human thyroid tissues since the inactivation of TGF-beta/activin signaling components is reported in several types of cancer.
  • Although TGF-beta and activin exert antiproliferative roles in thyroid follicular cells, thyroid tumors express high levels of these proteins.
  • MATERIALS AND METHODS: The protein expression of SMADs was evaluated in multinodular goiter, follicular adenoma, papillary and follicular carcinomas by immunohistochemistry.
  • RESULTS: The expression of pSMAD2/3, SMAD4 and SMAD7 was observed in both benign and malignant thyroid tumors.
  • Although pSMAD2/3, SMAD4 and SMAD7 exhibited high cytoplasmic staining in carcinomas, the nuclear staining of pSMAD2/3 was not different between benign and malignant lesions.
  • CONCLUSIONS: The finding of SMADs expression in thyroid cells and the presence of pSMAD2/3 and SMAD4 proteins in the nucleus of tumor cells indicates propagation of TGF-beta/activin signaling.
  • However, the high expression of the inhibitory SMAD7, mostly in malignant tumors, could contribute to the attenuation of the SMADs antiproliferative signaling in thyroid carcinomas.
  • [MeSH-major] Activins / physiology. Smad Proteins, Receptor-Regulated / metabolism. Thyroid Neoplasms / metabolism. Transforming Growth Factor beta / physiology
  • [MeSH-minor] Adenoma / metabolism. Carcinoma, Papillary, Follicular / metabolism. Goiter, Nodular / metabolism. Humans. Signal Transduction / physiology. Smad2 Protein / analysis. Smad3 Protein / analysis. Smad4 Protein / analysis. Smad7 Protein / analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20625653.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / SMAD2 protein, human; 0 / SMAD3 protein, human; 0 / SMAD4 protein, human; 0 / SMAD7 protein, human; 0 / Smad Proteins, Receptor-Regulated; 0 / Smad2 Protein; 0 / Smad3 Protein; 0 / Smad4 Protein; 0 / Smad7 Protein; 0 / Transforming Growth Factor beta; 104625-48-1 / Activins
  •  go-up   go-down


34. Ito Y, Uramoto H, Funa K, Yoshida H, Jikuzono T, Asahi S, Higashiyama T, Tomoda C, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A: Delta Np73 expression in thyroid neoplasms originating from follicular cells. Pathology; 2006 Jun;38(3):205-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delta Np73 expression in thyroid neoplasms originating from follicular cells.
  • In this study, we investigated the expression of delta Np73 in human thyroid neoplasms originating from follicular cells.
  • METHODS: We immunohistochemically investigated delta Np73 expression in 223 thyroid neoplasms.
  • RESULTS: Normal follicular cells did not express delta Np73, but 27.3% of follicular adenoma, 85.4% of follicular carcinoma, 99.2% of papillary carcinoma, and 95.7% of anaplastic carcinoma were positive for the transcript.
  • Delta Np73 expression level did not differ between widely invasive and minimally invasive follicular carcinomas.
  • [MeSH-major] Adenocarcinoma, Follicular / metabolism. Adenoma / metabolism. DNA-Binding Proteins / metabolism. Nuclear Proteins / metabolism. Thyroid Gland / metabolism. Thyroid Neoplasms / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753740.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


35. Deiana L, Lai ML, Carta G, Mariotti S: Correspondence between ultrasonography and histological features in a single thyroid nodule with coexisting follicular adenoma and papillary carcinoma. Thyroid; 2008 Jul;18(7):813-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correspondence between ultrasonography and histological features in a single thyroid nodule with coexisting follicular adenoma and papillary carcinoma.
  • [MeSH-major] Adenoma / pathology. Adenoma / ultrasonography. Carcinoma, Papillary / pathology. Carcinoma, Papillary / ultrasonography. Thyroid Neoplasms / ultrasonography. Thyroid Nodule / pathology. Thyroid Nodule / ultrasonography

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18631017.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


36. Yoshizawa K, Jelezcova E, Brown AR, Foley JF, Nyska A, Cui X, Hofseth LJ, Maronpot RM, Wilson SH, Sepulveda AR, Sobol RW: Gastrointestinal hyperplasia with altered expression of DNA polymerase beta. PLoS One; 2009 Aug 05;4(8):e6493
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These mice present with an elevated incidence of spontaneous histologic lesions, including cataracts, hyperplasia of Brunner's gland and mucosal hyperplasia in the duodenum.
  • We observed elevated expression of Pol beta in stomach adenomas and thyroid follicular carcinomas, but reduced Pol beta expression in esophageal adenocarcinomas and squamous carcinomas.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 2007 Jan;21(1):26-34 [17116746.001]
  • [Cites] Int J Cancer. 2007 Apr 15;120(8):1748-54 [17230526.001]
  • [Cites] DNA Repair (Amst). 2007 Jun 1;6(6):695-711 [17337257.001]
  • [Cites] Nucleic Acids Res. 2007;35(8):2596-608 [17426133.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1356-63 [17166880.001]
  • [Cites] Stem Cells. 2007 Dec;25(12):3085-92 [17823235.001]
  • [Cites] Mol Cell. 2008 Feb 29;29(4):413-5 [18313379.001]
  • [Cites] Mol Cell. 2008 Feb 29;29(4):477-87 [18313385.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jun 27;371(2):225-9 [18433721.001]
  • [Cites] Mol Pharmacol. 2008 Aug;74(2):505-16 [18477668.001]
  • [Cites] Chin Med Sci J. 2008 Jun;23(2):108-12 [18686630.001]
  • [Cites] Cancer Lett. 2008 Nov 28;271(2):272-80 [18662849.001]
  • [Cites] Biol Reprod. 2008 Nov;79(5):824-31 [18650495.001]
  • [Cites] Gene. 2009 Jan 1;428(1-2):20-4 [18976699.001]
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):740-6 [19147782.001]
  • [Cites] Carcinogenesis. 2009 May;30(5):763-8 [19237606.001]
  • [Cites] Cancer Res. 2009 Jun 15;69(12):5177-85 [19491276.001]
  • [Cites] J Biol Chem. 2004 Oct 15;279(42):43952-60 [15297456.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(21):9470-7 [15485914.001]
  • [Cites] Cell Cycle. 2004 Aug;3(8):998-1001 [15280658.001]
  • [Cites] J Natl Cancer Inst. 1969 Dec;43(6):1353-64 [5396221.001]
  • [Cites] Cancer Res. 1975 Aug;35(8):1938-43 [1149018.001]
  • [Cites] Lab Anim Sci. 1983 Jun;33(3):273-86 [6876733.001]
  • [Cites] Cancer Lett. 1984 Nov;25(1):19-23 [6518449.001]
  • [Cites] J Comp Pathol. 1986 Jan;96(1):89-94 [3455952.001]
  • [Cites] Lab Anim. 1989 Oct;23(4):324-7 [2811271.001]
  • [Cites] Exp Pathol. 1990;38(2):129-34 [2344869.001]
  • [Cites] Cancer Res. 1992 Sep 1;52(17):4824-7 [1511447.001]
  • [Cites] Science. 1994 Jul 1;265(5168):103-6 [8016642.001]
  • [Cites] Lab Anim Sci. 1994 Oct;44(5):531-3 [7844967.001]
  • [Cites] Cancer Lett. 1995 May 8;91(2):177-83 [7767907.001]
  • [Cites] Nature. 1996 Jan 11;379(6561):183-6 [8538772.001]
  • [Cites] Lab Invest. 1996 Feb;74(2):513-8 [8780168.001]
  • [Cites] J Exp Zool. 1997 Feb 15;277(3):245-54 [9062998.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10324-9 [9294209.001]
  • [Cites] Vet Pathol. 1997 Nov;34(6):605-14 [9396142.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9997-10002 [9707589.001]
  • [Cites] Carcinogenesis. 1999 Jun;20(6):1049-54 [10357787.001]
  • [Cites] Carcinogenesis. 1999 Sep;20(9):1825-30 [10469630.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7673-7 [15520167.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8526-33 [15574758.001]
  • [Cites] Nucleic Acids Res. 2005;33(1):280-8 [15647510.001]
  • [Cites] J Invest Surg. 2004 Nov-Dec;17(6):327-31 [15764500.001]
  • [Cites] DNA Repair (Amst). 2005 May 2;4(5):583-93 [15811630.001]
  • [Cites] EMBO J. 2005 Jul 6;24(13):2447-57 [15933716.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6113-7 [10626800.001]
  • [Cites] EMBO J. 2000 Mar 15;19(6):1397-404 [10716939.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):807-10 [10866204.001]
  • [Cites] Leuk Res. 2000 Aug;24(8):705-18 [10936423.001]
  • [Cites] Carcinogenesis. 2000 Sep;21(9):1691-700 [10964101.001]
  • [Cites] Mol Cell Biol. 2001 Jan;21(1):298-309 [11113204.001]
  • [Cites] Science. 2001 Feb 16;291(5507):1284-9 [11181991.001]
  • [Cites] Langenbecks Arch Surg. 2001 Apr;386(3):163-71 [11382316.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6181-7 [11593426.001]
  • [Cites] J Mol Biol. 2002 Feb 1;315(5):1039-47 [11827474.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1524-30 [11888930.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6860-5 [11983862.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3511-4 [12067997.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6061-4 [12414629.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1213-22 [12453427.001]
  • [Cites] DNA Repair (Amst). 2002 Apr 29;1(4):317-33 [12509250.001]
  • [Cites] Curr Gastroenterol Rep. 2003 Apr;5(2):171-5 [12631460.001]
  • [Cites] DNA Repair (Amst). 2003 May 13;2(5):609-22 [12713817.001]
  • [Cites] Pathologe. 2003 May;24(3):196-203 [12739053.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5799-807 [14522902.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39951-9 [12882965.001]
  • [Cites] J Clin Invest. 2003 Dec;112(12):1887-94 [14679184.001]
  • [Cites] FEBS Lett. 2004 May 21;566(1-3):147-50 [15147885.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3830-7 [15172990.001]
  • [Cites] Mol Cancer Ther. 2004 Aug;3(8):955-67 [15299078.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(4):223-31 [15368105.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6394-400 [16024643.001]
  • [Cites] Cell. 2005 Sep 23;122(6):957-68 [16169070.001]
  • [Cites] Mutagenesis. 2006 Jan;21(1):55-9 [16399847.001]
  • [Cites] Mol Cell. 2006 Apr 7;22(1):51-62 [16600869.001]
  • [Cites] Dis Esophagus. 2006;19(3):172-6 [16722994.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1B):523-5 [16739313.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7460-5 [16885342.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1261-9 [16799479.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5104-11 [16951227.001]
  • [Cites] Cell. 2006 Nov 17;127(4):709-20 [17110331.001]
  • (PMID = 19654874.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / 1 R01 AG24364-01; United States / NIEHS NIH HHS / ES / Z01 ES050158; United States / NIEHS NIH HHS / ES / Z01 ES050159; United States / NIA NIH HHS / AG / R01 AG024364; United States / NCI NIH HHS / CA / 1P50 CA 097190 01A1; United States / NCI NIH HHS / CA / 1 P20 CA132385-01; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / P20 CA132385; United States / NCI NIH HHS / CA / P50 CA097190; United States / NCI NIH HHS / CA / P20 CA103730
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.- / DNA Polymerase beta
  • [Other-IDs] NLM/ PMC2716528
  •  go-up   go-down


37. Tate G, Suzuki T, Endo Y, Mitsuya T: A novel mutation of the PTEN gene in a Japanese patient with Cowden syndrome and bilateral breast cancer. Cancer Genet Cytogenet; 2008 Jul;184(1):67-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cowden syndrome (CS), also known as multiple hamartoma syndrome, is an autosomal dominant cancer syndrome associated with a high risk of breast and thyroid cancers.
  • The phosphatase and tensin homolog gene (PTEN) encodes a lipid phosphatase that contains a PTPase domain and a C2 domain and plays a role as a tumor suppressor that negatively regulates the cell-survival signaling pathway initiated by phosphatidylinositol 3-kinase (PI3K).
  • In one patient, who suffered from bilateral breast cancer, thyroid adenoma, and gastric malignant lymphoma, we found a single-base substitution in exon 2 (115G>C) of the PTEN gene.
  • [MeSH-minor] Adenoma / complications. Adenoma / genetics. Base Sequence. DNA Primers. Female. Humans. Polymerase Chain Reaction. Thyroid Neoplasms / complications. Thyroid Neoplasms / genetics


38. Garg M, Kanojia D, Suri S, Gupta S, Gupta A, Suri A: Sperm-associated antigen 9: a novel diagnostic marker for thyroid cancer. J Clin Endocrinol Metab; 2009 Nov;94(11):4613-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sperm-associated antigen 9: a novel diagnostic marker for thyroid cancer.
  • CONTEXT: Cancer-testis antigens are the unique class of testis proteins expressed in tumor but not healthy tissue except testis and might represent ideal targets for the development of novel diagnostics and therapeutic methods in thyroid cancer, which is the most common malignancy of the endocrine system.
  • OBJECTIVE: Our objective was to investigate the clinical relevance of cancer-testis antigen sperm-associated antigen 9 (SPAG9) as early diagnostic and therapeutic target in thyroid cancer.
  • DESIGN, SETTING, AND SUBJECTS: SPAG9 gene and protein expression was determined in thyroid cancer cell lines in 138 thyroid tumor specimens, 60 adjacent noncancerous tissues (ANCT), 22 multinodular goiters (nonneoplastic hyperplasia), and 20 follicular adenoma tissue samples by RT-PCR, in situ RNA hybridization, and immunohistochemistry.
  • Humoral immune response against SPAG9 in thyroid cancer patients was analyzed using ELISA.
  • RESULTS: SPAG9 mRNA and protein expression was detected in 78% of the thyroid cancer patients but not multiple goiters and follicular adenoma disease patients.
  • It is interesting to note that majority of early-stage (T1) thyroid cancer patients exhibited higher antibody response against SPAG9.
  • Small interfering RNA-mediated knockdown of SPAG9 expression in thyroid cancer cell significantly reduced cellular growth and colony formation.
  • CONCLUSIONS: SPAG9 expression may play a role in cellular growth and thyroid carcinogenesis.
  • These findings support a potential role for SPAG9 as diagnostic biomarker as well as a possible therapeutic target in thyroid cancer treatment.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Biomarkers, Tumor / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Cell Division. Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay. Gene Expression Regulation, Neoplastic. Goiter / blood. Humans. Immunohistochemistry. Neoplasm Staging. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820019.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / SPAG9 protein, human
  •  go-up   go-down


39. Walter MA, Seboek D, Demougin P, Bubendorf L, Oberholzer M, Müller-Brand J, Müller B: Extraction of high-integrity RNA suitable for microarray gene expression analysis from long-term stored human thyroid tissues. Pathology; 2006 Jun;38(3):249-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraction of high-integrity RNA suitable for microarray gene expression analysis from long-term stored human thyroid tissues.
  • INTRODUCTION: Isolation of high-quality RNA from fresh-frozen thyroid tissues stored for more than a decade would open novel options for gene expression profiling.
  • Herein, we describe successful extraction of high-integrity RNA from human thyroid tissues that were stored for more than a decade.
  • METHODS: Seventy-nine samples (15 goitres, 20 follicular adenomas, 30 papillary carcinomas, 14 follicular carcinomas) that were shock-frozen in isopentane and stored for a median of 11 years (range 1-16 years) were processed using standard precipitation and column filtration techniques.
  • RESULTS: The median RNA yield was 1.9 microg/mg tissue (papillary carcinoma 2.1 microg/mg, range 0.2-7.2 microg/mg; follicular carcinoma 2.4 microg/mg, range 0.2-3.2 microg/mg; goitre 1.4 microg/mg, range 0.1-5.4 microg/mg; follicular adenoma 1.6 microg/mg, range 0.1-6.2 microg/mg; p = 0.46) with an 8.6 (7.3-9.8) median RIN.
  • CONCLUSIONS: Age and entity independent RNA suitable for expression profiling can be extracted from long-term stored fresh-frozen human thyroid tissues.
  • [MeSH-major] Gene Expression Profiling. Oligonucleotide Array Sequence Analysis. RNA / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Follicular / chemistry. Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Adenoma / chemistry. Adenoma / genetics. Adenoma / pathology. Carcinoma, Papillary / chemistry. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Glyceraldehyde-3-Phosphate Dehydrogenases / genetics. Glyceraldehyde-3-Phosphate Dehydrogenases / metabolism. Goiter / genetics. Goiter / metabolism. Goiter / pathology. Humans. Organ Preservation. Thyroid Gland. Time Factors

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753748.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 63231-63-0 / RNA; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


40. Maji D: Hyperthyroidism. J Indian Med Assoc; 2006 Oct;104(10):563-4, 566-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hyperthyroidism is a clinical situation where there is excess thyroid hormones in the circulation due to increased synthesis of hormone from a hyperactive thyroid gland.
  • Excess thyroid hormones in the circulation are also found in thyroiditis (hormone leakage) and excess exogenous thyroxine intake.
  • Thyrotoxicosis is the term applied when there is excess thyroid hormone in the circulation due to any cause.
  • Thyrotoxicosis can be easily diagnosed by high serum level of thyroxine (T4) and triiodothyronine (T3) and low serum level of thyroid stimulating hormone (TSH).
  • Hyperthyroidism is confirmed by high isotope (I 131 or Tc99) uptake by the thyroid gland, while in thyroiditis it will be low.
  • Surgery is the preferred treatment for toxic adenoma and toxic multinodular goitre, while 1131 therapy may be suitable in some cases.
  • [MeSH-major] Hyperthyroidism / diagnosis
  • [MeSH-minor] Graves Disease / physiopathology. Humans. Risk Factors. Thyrotoxicosis / diagnosis. Thyrotoxicosis / physiopathology

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17380820.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 11
  •  go-up   go-down


41. Dewil B, Van Damme B, Vander Poorten V, Delaere P, Debruyne F: Completion thyroidectomy after the unexpected diagnosis of thyroid cancer. B-ENT; 2005;1(2):67-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Completion thyroidectomy after the unexpected diagnosis of thyroid cancer.
  • The optimal surgical management of well-differentiated thyroid cancer (DTC) remains a controversial topic.
  • Preoperative and peroperative investigations quite frequently fail to detect thyroid cancer in cold nodules, and only postoperative histological examination reveals malignancy.
  • We reviewed the records of 29 patients--25 women and 4 men-- who all underwent completion thyroidectomy because of an unexpected diagnosis of DTC.
  • Because of the rather low re-operation rate, we prefer to perform a completion thyroidectomy to remove potential occult malignancy and to allow for postoperative 131I-treatment in all patients with a diagnosis of malignancy in their thyroid lobectomy specimen, with the exception of papillary carcinoma < 1 cm.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / surgery. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / surgery. Thyroidectomy / methods
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / surgery. Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / surgery. Adolescent. Adult. Aged. Biopsy, Fine-Needle. Female. Humans. Male. Middle Aged. Neoplasm, Residual. Retrospective Studies. Thyroid Gland / pathology. Thyroid Gland / radionuclide imaging. Thyroid Gland / ultrasonography. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044737.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


42. Pisello F, Geraci G, Sciumè C, Li Volsi F, Modica G: [Total thyroidectomy of choice in papillary microcarcinoma]. G Chir; 2007 Jan-Feb;28(1-2):13-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La tiroidectomia totale di principio nel microcarcinoma papillare.
  • INTRODUCTION: Today, the "gold standard" of surgical management of benign thyroid disease is still controversy.
  • There are different surgical approaches to the thyroid gland, from a radical, total thyroidectomy to a conservative treatment, lobectomy with or not isthmectomy.
  • In consideration of the more frequent incidence of small carcinomas accidentally founded in the context of the thyroid parenchyma removed for another pathology, the aim of this study is to bring a contribute to resolve the debate on the therapeutic choice in the surgical management of the thyroid benign disease.
  • PATIENTS AND METHODS: From January 2000 to January 2006 502 thyroidectomy were performed in the Section of General and Thoracic Surgery of University of Palermo: 458 total thyroidectomy (91.3%), 2 partial thyroidectomy (0.3%), 24 (4.8%) lobectomy with isthmectomy and 18 (3.6%) reinterventions for relapse; 34 patients (6.8%) were preoperative suspected (cytological or ultrasonography) for thyroid cancer.
  • Histologically, were 11 cases of classical papillary (64.7%), 4 cases (23.6%) of follicular and 2 (11.7%) sclerosing, in 9 cases of multinodular goiter, 3 of follicular adenoma, 3 cases of follicular carcinoma, 1 case of Graves disease and 1 case of Hashimoto thyroiditis.
  • DISCUSSION: Papillary microcarcinoma is a "thyroid papillary cancer with a diameter < or = 1 cm? ".
  • CONCLUSIONS: In our opinion, the surgical management of the all thyroid disease must be the more radical since the first time, because we think other approaches not correct to improve the complete health from the benign thyroid disease and to prevent (secondary prevention) papillary microcarcinoma not pre-operative diagnosed, because there are no preoperative pattern to make a correct diagnosis of this tumour.
  • [MeSH-major] Carcinoma, Papillary / surgery. Thyroid Neoplasms / surgery. Thyroidectomy / methods

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313727.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


43. Kim KH, Kim SH, Kim SH, Back JH, Park MJ, Kim JM: Cyclooxygenase-2 and inducible nitric oxide synthase expression in thyroid neoplasms and their clinicopathological correlation. J Korean Med Sci; 2006 Dec;21(6):1064-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 and inducible nitric oxide synthase expression in thyroid neoplasms and their clinicopathological correlation.
  • To evaluate the expressions of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) in thyroid neoplasms in a Korean population, we studied a total of 154 cases: papillary carcinoma of classical type (PTC), 86; follicular adenoma (FA), 21; follicular carcinoma (FC), 35; medullary carcinoma (MC), 3; undifferentiated carcinoma (UC), 5; and Hurthle cell neoplasm (HN), 4.
  • These results suggest that the upregulation of COX-2 and iNOS may contribute to the tumor progression of thyroid gland, particularly in PTC and HN, and iNOS may play an adjuvant role during the tumor progression of FC.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cyclooxygenase 2 / analysis. Neoplasm Proteins / analysis. Nitric Oxide Synthase Type II / analysis. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 1998 Sep;12(12):1063-73 [9737710.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1998;38:97-120 [9597150.001]
  • [Cites] Thyroid. 1999 Feb;9(2):113-7 [10090309.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Sep;281(3):G688-96 [11518681.001]
  • [Cites] J Clin Gastroenterol. 2001 Nov-Dec;33(5):383-8 [11606854.001]
  • [Cites] Ann Clin Lab Sci. 2001 Oct;31(4):325-48 [11688844.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):358-63 [11788675.001]
  • [Cites] J Pathol. 2002 Feb;196(2):171-9 [11793368.001]
  • [Cites] Laryngoscope. 2002 Feb;112(2):238-42 [11889377.001]
  • [Cites] Am J Clin Pathol. 2002 Apr;117(4):546-51 [11939728.001]
  • [Cites] Prostate. 2002 Nov 1;53(3):232-40 [12386924.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):961-8 [12631593.001]
  • [Cites] Endocr Pathol. 2002 Winter;13(4):331-40 [12665651.001]
  • [Cites] Histopathology. 2003 May;42(5):492-7 [12713627.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1604-10 [12738712.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):434-9 [12828608.001]
  • [Cites] Korean J Intern Med. 2003 Dec;18(4):225-9 [14717230.001]
  • [Cites] Histopathology. 2004 May;44(5):490-7 [15139997.001]
  • [Cites] Br J Pharmacol. 1993 Mar;108(3):833-7 [7682140.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1352-4 [7509718.001]
  • [Cites] Cell. 1994 Sep 23;78(6):915-8 [7522969.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):727-30 [7531613.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] J Clin Invest. 1997 Jun 1;99(11):2625-34 [9169492.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):645-9 [9237172.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4926-31 [10987308.001]
  • [Cites] BJU Int. 2000 Oct;86(6):736-41 [11069387.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):303-8 [11196178.001]
  • [Cites] Antioxid Redox Signal. 2001 Apr;3(2):231-48 [11396478.001]
  • [Cites] Int J Urol. 2001 Jul;8(7):S35-9 [11442675.001]
  • [Cites] J Immunol. 1997 Sep 1;159(5):2445-51 [9278337.001]
  • [Cites] J Biol Chem. 1997 Dec 5;272(49):31138-48 [9388267.001]
  • [Cites] Cancer Metastasis Rev. 1998 Mar;17(1):107-18 [9544426.001]
  • [Cites] Laryngoscope. 1999 Jan;109(1):148-52 [9917057.001]
  • (PMID = 17179688.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ PMC2721930
  •  go-up   go-down


44. Mai KT, Elmontaser G, Perkins DG, Thomas J, Stinson WA: Benign Hürthle cell adenoma with papillary architecture: a benign lesion mimicking oncocytic papillary carcinoma. Int J Surg Pathol; 2005 Jan;13(1):37-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign Hürthle cell adenoma with papillary architecture: a benign lesion mimicking oncocytic papillary carcinoma.
  • We studied the significance of encapsulated Hürthle cell thyroid nodules with papillary structures lacking the nuclear features of papillary thyroid carcinoma (PTC); 19 cases fulfilling these criteria were encountered The patients' ages ranged from 22 to 40 years (32+/-6), and the F:M ratio was 3:1 The tumors measured from 0.5-5 cm (2+/-1.1).
  • The diameter of the tumor cell nuclei ranged from 5.6 to 7.2 microns.
  • In view of (1) the encapsulation and the uniformity of the constituent cells, (2) the negative or weak immunoreactivity for galectin-3 and HBME and negative to moderate immunoreactivity for CK19, and (3) the absence or paucity of nuclear criteria for the diagnosis of PTC and the absence of lymph node metastasis in all study cases, we believe that these lesions represent the papillary variant of oncocytic follicular adenoma (Hürthle cell adenoma).
  • [MeSH-major] Adenoma / pathology. Adenoma, Oxyphilic / pathology. Carcinoma, Papillary, Follicular / diagnosis. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Chromatin / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735853.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromatin
  •  go-up   go-down


45. Hamada N, Noh JY, Okamoto Y, Ueda M, Konishi T, Fujisawa T, Ito K, Ito K: Measuring thyroglobulin autoantibodies by sensitive assay is important for assessing the presence of thyroid autoimmunity in areas with high iodine intake. Endocr J; 2010;57(7):645-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measuring thyroglobulin autoantibodies by sensitive assay is important for assessing the presence of thyroid autoimmunity in areas with high iodine intake.
  • There is some debate over the clinical utility of measuring serum TgAb to assess the presence of thyroid autoimmunity.
  • To clarify the relationship between TgAb levels and thyroid autoimmunity, a histological examination of thyroid tissue was carried out on unselected living individuals with detectable serum TgAb.
  • 146 patients with a pathological diagnosis of follicular adenoma were selected as subjects.
  • A thyroid gland in which 0-1 FLI was observed in a few visual fields of low magnification (20 x 4) in thyroid tissue adjacent to a tumor was judged to be normal and a thyroid gland in which 2 or more FLI were observed was diagnosed as focal lymphocytic thyroiditis (FLT).
  • These results throw doubt on the Laboratory medicine practice guidelines published in Thyroid 2003, in which measuring TgAb is not usually necessary for detecting autoimmune thyroid disease.
  • At least measuring TgAb by sensitive assay is useful for assessing the presence of thyroid autoimmunity in Japan, an area with high iodine intakes.
  • [MeSH-major] Autoantibodies / analysis. Iodine / supply & distribution. Thyroglobulin / immunology. Thyroiditis, Autoimmune / diagnosis

  • Hazardous Substances Data Bank. IODINE, ELEMENTAL .
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20467162.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Autoantibodies; 9010-34-8 / Thyroglobulin; 9679TC07X4 / Iodine
  •  go-up   go-down


46. Tabriz HM, Adabi Kh, Lashkari A, Heshmat R, Haghpanah V, Larijani B, Tavangar SM: Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm. Pathol Res Pract; 2009;205(2):83-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm.
  • INTRODUCTION: We aimed at assessing the significance of nm23 gene expression in papillary and follicular carcinomas, the two most common differentiated thyroid carcinomas.
  • MATERIALS AND METHODS: During a cross-sectional study, 173 paraffin blocks, including 131 papillary thyroid carcinomas, 12 follicular carcinomas and 30 follicular adenomas were stained with nm23 marker by immunohistochemistry method.
  • RESULTS: nm23 was positive in 40% of the follicular adenoma, 67.2% of the papillary carcinoma and 66.7% of the follicular carcinoma. p value was more than 0.05 in the assessment of the relationship between nm23 and all of the above-mentioned parameters in differentiated thyroid carcinomas. nm23 expression did not significantly differentiate between follicular adenoma and carcinoma.
  • Also, nm23 cannot be considered as a useful marker for the evaluation of invasion in differentiated thyroid carcinomas or in distinctions between follicular adenoma and carcinoma.
  • [MeSH-major] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Papillary / metabolism. Adenoma / metabolism. NM23 Nucleoside Diphosphate Kinases / biosynthesis. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18996649.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NM23 Nucleoside Diphosphate Kinases; EC 2.7.4.6 / NME1 protein, human
  •  go-up   go-down


47. Gurleyik E, Coskun O, Aslaner A: Clinical importance of solitary solid nodule of the thyroid in endemic goiter region. Indian J Med Sci; 2005 Sep;59(9):388-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical importance of solitary solid nodule of the thyroid in endemic goiter region.
  • CONTEXT: Endemic area and iodine supplementation may affect the pathogenesis of the nodule which commonly occurs in endemic thyroid enlargement due to iodine deficiency.
  • AIMS: To establish pathological changes in solitary solid and larger nodule of the thyroid in endemic area.
  • The thyroid nodule was preoperatively evaluated with blood chemistry, ultrasound, nuclear scanning and FNAC.
  • RESULTS: Twenty (45%;20/44) patients with hot (autonomous) nodule have received the diagnosis of toxic adenoma.
  • CONCLUSIONS: Solitary solid and large nodule is a common indication for thyroid surgery in endemic goiter area.
  • High incidence of hyperthyroidism due to single autonomous nodule, and high rate of malignant change (mainly papillary cancer) in solitary hypoactive nodule arises from this series in endemic thyroid enlargement.
  • [MeSH-major] Goiter, Endemic / diagnosis. Thyroid Nodule / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers / blood. Biopsy, Fine-Needle. Diagnosis, Differential. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Thyroid Gland / pathology. Thyroid Gland / radionuclide imaging. Thyroid Gland / ultrasonography. Thyroidectomy. Thyrotropin / blood. Thyroxine / blood. Treatment Outcome. Triiodothyronine / blood

  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Indian J Med Sci. 2006 Jun;60(6):246-7; author reply 247-8 [16790952.001]
  • (PMID = 16199924.001).
  • [ISSN] 0019-5359
  • [Journal-full-title] Indian journal of medical sciences
  • [ISO-abbreviation] Indian J Med Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers; 06LU7C9H1V / Triiodothyronine; 9002-71-5 / Thyrotropin; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


48. Savin S, Cvejic D, Isic T, Paunovic I, Tatic S, Havelka M: Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation. Hum Pathol; 2008 Nov;39(11):1656-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
  • Thyroperoxidase and galectin-3 have been reported as useful immunohistochemical markers of thyroid malignancy.
  • In this study, we evaluated the relationship between immunohistochemical staining results for these markers and clinicopathologic features of patients with differentiated thyroid cancer.
  • A total of 193 archival thyroid samples including 28 follicular adenomas, 18 follicular carcinomas, and 147 papillary carcinomas with 114 adjacent thyroid tissues were analyzed by immunohistochemistry.
  • The sensitivity for diagnosis of differentiated thyroid carcinoma was 86.1% for thyroperoxidase and 82.4% for galectin-3, whereas the combination of both markers increased the sensitivity up to 94.5%.
  • In patients with follicular carcinoma, the extent of invasiveness was associated with galectin-3 positivity.
  • Thus, expression of these markers is related to more or less aggressive biological behavior of differentiated thyroid carcinomas.
  • Although thyroperoxidase presence may indicate favorable prognosis of papillary cancer, expression of galectin-3 illustrates the potential importance of this protein in the pathogenesis and/or progression of differentiated thyroid carcinomas.
  • [MeSH-major] Galectin 3 / metabolism. Iodide Peroxidase / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adenoma / metabolism. Adenoma / pathology. Adult. Biomarkers, Tumor / metabolism. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Sensitivity and Specificity. Thyroid Gland / metabolism. Thyroid Gland / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18657294.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


49. Shikama Y, Mizukami H, Sakai T, Yagihashi N, Okamoto K, Yagihashi S: Spindle cell metaplasia arising in thyroid adenoma: characterization of its pathology and differential diagnosis. J Endocrinol Invest; 2006 Feb;29(2):168-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spindle cell metaplasia arising in thyroid adenoma: characterization of its pathology and differential diagnosis.
  • Spindle cell metaplasia in thyroid adenoma or carcinoma is rare and its pathological features are not well characterized.
  • We encountered a case of thyroid follicular adenoma associated with spindle cell metaplasia.
  • It showed "tumor in tumor appearance" and neoplastic spindle cells were positive for thyroglobulin, thyroid transcription factor-1, vimentin and focally chromogranin A and somatostatin (SS).
  • Ultrastructure of the spindle cells was reminiscent of follicular cell origin.
  • From the findings from our case, spindle cell metaplasia appears to be a benign clinical entity, suggestive of multidirectional differentiation of follicular cells.
  • [MeSH-major] Adenoma / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Metaplasia / pathology. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2004 Jan;128(1):87-9 [14692805.001]
  • [Cites] Arch Pathol Lab Med. 1994 Nov;118(11):1143-7 [7979902.001]
  • [Cites] Am J Surg. 1965 Oct;110(4):660-8 [5825178.001]
  • [Cites] Semin Diagn Pathol. 2000 May;17(2):109-19 [10839611.001]
  • [Cites] Mod Pathol. 1997 May;10(5):510-4 [9160319.001]
  • [Cites] Am J Clin Pathol. 1985 Feb;83(2):135-58 [2578727.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1):70-4 [9894456.001]
  • [Cites] Virchows Arch. 2005 Jan;446(1):91-2 [15517364.001]
  • [Cites] Am J Clin Pathol. 1991 Mar;95(3):309-14 [1996541.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1424-8 [11684960.001]
  • [Cites] Mod Pathol. 2003 Jan;16(1):43-8 [12527712.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):199-204 [11863215.001]
  • [Cites] Genes Chromosomes Cancer. 1993 Apr;6(4):239-42 [7685628.001]
  • (PMID = 16610245.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


50. Patel MR, Bryson PC, Shores CG, Hart CF, Thorne LB, Deal AM, Zanation AM: Trefoil factor 3 immunohistochemical characterization of follicular thyroid lesions from tissue microarray. Arch Otolaryngol Head Neck Surg; 2009 Jun;135(6):590-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trefoil factor 3 immunohistochemical characterization of follicular thyroid lesions from tissue microarray.
  • OBJECTIVES: To characterize trefoil factor 3 (TFF3) expression in normal thyroid tissue samples compared with that in follicular adenoma, follicular carcinoma, and follicular variant of papillary thyroid carcinoma using immunohistochemistry on tissue microarrays.
  • DESIGN: Immunohistochemical analysis of 83 normal thyroid tissue and of 83 follicular neoplasms (26 follicular adenomas, 25 follicular variant of papillary thyroid carcinoma, 23 follicular thyroid carcinomas, and 9 papillary thyroid carcinomas) was performed using an antibody to TFF3 on tissue microarray sections composed of formalin-fixed, paraffin-embedded tissue samples.
  • PATIENTS: Thyroid tissue samples collected from patients over a 15-year period were obtained from the University of North Carolina Hospitals Division of Surgical Pathology archives.
  • MAIN OUTCOME MEASURES: Thyroid tissue samples were graded by a pathologist based on intensity of antibody staining and on percentage of cells stained.
  • Data were analyzed for semiquantitative differences in immunohistochemical intensity of antibody staining and in percentage of cells stained among normal thyroid tissue samples, follicular adenoma, follicular thyroid carcinoma, follicular variant of papillary thyroid carcinoma, and papillary thyroid carcinoma.
  • RESULTS: Semiquantitative analysis demonstrated that immunohistochemistry detects significant levels of TFF3 expression in normal thyroid tissue samples compared with that in follicular lesions based on intensity of antibody staining (P < .05).
  • Only follicular thyroid carcinoma demonstrated a significant reduction in percentage of cells stained compared with that in normal thyroid tissue samples (P = .03).
  • No significant differences in intensity of antibody staining or in the percentage of cells stained were noted among follicular adenoma, follicular thyroid carcinoma, follicular variant of papillary thyroid carcinoma, or papillary thyroid carcinoma.
  • CONCLUSIONS: Protein expression data validate gene expression findings that follicular neoplastic lesions have decreased expression of TFF3 compared with that in normal thyroid tissue samples.
  • These findings contribute to evidence suggesting that TFF3 may have a role in normal thyroid tissue function and that thyroid carcinomas may have reduced expression of TFF3, in contradistinction to other carcinomas that overexpress TFF3.
  • [MeSH-major] Adenoma / metabolism. Carcinoma, Papillary, Follicular / metabolism. Peptides / metabolism. Protein Array Analysis. Thyroid Gland / metabolism. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19528408.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptides; 0 / TFF3 protein, human
  •  go-up   go-down


51. Bradly DP, Reddy V, Prinz RA, Gattuso P: Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases. Surgery; 2009 Dec;146(6):1099-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases.
  • BACKGROUND: The frequency of incidental papillary carcinoma (IPC) has been reported to be between 4.6 % and 10% in operatively treated benign thyroid diseases.
  • This study reviews the occurrence of IPC in thyroid glands removed for benign disease at our institution.
  • METHODS: Six hundred and seventy-eight patients underwent partial or total thyroidectomy for benign thyroid diseases.
  • The incidence of IPC was compared among patients with Hashimoto's thyroiditis, multinodular goiter, follicular adenoma, and Graves' disease.
  • RESULTS: Overall, 81 (12.0%) IPCs were recorded with decreasing order of frequency: Hashimoto's thyroiditis, follicular adenoma, goiter, and Graves' disease.
  • Contralateral IPC was detected in 6/15 (40%) patients with follicular adenoma.
  • CONCLUSION: The overall incidence of IPC in benign operatively resected thyroid disease was 12%.
  • IPC was encountered in the contralateral lobe in 40% of patients with follicular adenoma.
  • The association of IPCs with Hashimoto's thyroiditis may indicate a link to thyroid cancer.
  • Total thyroidectomy may be considered an appropriate operative treatment in patients with Hashimoto's thyroiditis and follicular adenoma requiring operation owing to the high incidence and frequent contralateral involvement of IPC, respectively.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Thyroid Diseases / surgery. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Chicago / epidemiology. Female. Goiter, Nodular / complications. Goiter, Nodular / surgery. Graves Disease / complications. Graves Disease / surgery. Hashimoto Disease / complications. Hashimoto Disease / surgery. Humans. Male. Middle Aged. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / epidemiology. Neoplasms, Multiple Primary / surgery. Thyroidectomy. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958937.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Steele SR, Martin MJ, Mullenix PS, Azarow KS, Andersen CA: The significance of incidental thyroid abnormalities identified during carotid duplex ultrasonography. Arch Surg; 2005 Oct;140(10):981-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of incidental thyroid abnormalities identified during carotid duplex ultrasonography.
  • HYPOTHESIS: Incidental thyroid masses identified during carotid duplex ultrasonography may represent clinically significant lesions.
  • INTERVENTIONS: After bilateral carotid duplex ultrasonography, selected patients additionally underwent 1 or more of the following: dedicated thyroid ultrasound, fine-needle aspiration biopsy, and/or partial or total thyroidectomy.
  • MAIN OUTCOME MEASURES: The prevalence and type of thyroid abnormalities, correlation with a dedicated thyroid ultrasound, and results of histopathologic diagnosis.
  • RESULTS: One or more thyroid abnormalities were identified in 188 duplexes (9.4%) involving 168 patients.
  • Sixty-six of the patients (40%) went on to have formal thyroid ultrasounds.
  • Surgical pathology included 5 patients with cancer (3 with papillary cancer, 2 with follicular cancer), 4 patients with a follicular adenoma, and 2 with lymphocytic thyroiditis).
  • Two additional patients were discovered to have parathyroid adenomas following further workup and surgery.
  • Thyroid abnormalities identified during carotid duplex ultrasonography correlated with formal ultrasound in 64 of 66 (97%) patients.
  • Measurement of the thyroid mass by carotid duplex strongly correlated with measurement by formal thyroid ultrasound (r = 0.95, P<.001).
  • Two patients with unilateral masses noted on carotid duplex had a normal thyroid formal ultrasound.
  • CONCLUSIONS: Incidental thyroid abnormalities identified during carotid duplex ultrasound are common and contain clinically significant pathology.
  • [MeSH-major] Carotid Artery Diseases / ultrasonography. Thyroid Neoplasms / ultrasonography
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Incidental Findings. Male. Middle Aged. Retrospective Studies. Thyroid Diseases / surgery. Thyroid Diseases / ultrasonography. Ultrasonography, Doppler, Duplex

  • MedlinePlus Health Information. consumer health - Carotid Artery Disease.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16230549.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Carpinteri R, Patelli I, Casanueva FF, Giustina A: Pituitary tumours: inflammatory and granulomatous expansive lesions of the pituitary. Best Pract Res Clin Endocrinol Metab; 2009 Oct;23(5):639-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphocytic hypophysitis is the most relevant of these disorders, and it is characterised by autoimmune pathogenesis with focal or diffuse inflammatory infiltration and varying degrees of pituitary gland destruction.
  • Pituitary abscess is a rare but potentially life-threatening disease and, in 30-50% of patients, anterior pituitary hormone deficiencies or central diabetes insipidus (DI) at onset may be observed: the earliest manifestation being growth hormone deficiency (GHD), followed by follicle-stimulating hormone (FSH)/luteinising hormone (LH), thyroid-stimulating hormone (TSH) and ACTH deficiencies.
  • DI is reported in approximately 25-33 % of all neurosarcoidosis cases and is the most frequently observed endocrine disorder.
  • Other forms of granulomatous pituitary lesions include idiopathic giant cell granulomatous hypophysitis, Takayasu's disease, Cogan's syndrome and Crohn's disease.
  • In conclusion, in patients with a sellar mass and unusual clinical presentation (DI, neurological symptoms), aggressiveness and onset and in the presence of systemic diseases, inflammatory and granulomatous pituitary lesions should be carefully considered in differential diagnosis.
  • [MeSH-major] Adenoma / complications. Granuloma / etiology. Inflammation / etiology. Pituitary Diseases / etiology. Pituitary Neoplasms / complications
  • [MeSH-minor] Communicable Diseases / complications. Communicable Diseases / etiology. Erdheim-Chester Disease / etiology. Granulomatosis with Polyangiitis / etiology. Histiocytosis, Langerhans-Cell / etiology. Humans. Pituitary Gland / pathology. Sarcoidosis / etiology

  • MedlinePlus Health Information. consumer health - Pituitary Disorders.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19945028.001).
  • [ISSN] 1878-1594
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 107
  •  go-up   go-down


54. Cassol CA, Guo M, Ezzat S, Asa SL: GNAq mutations are not identified in papillary thyroid carcinomas and hyperfunctioning thyroid nodules. Endocr Pathol; 2010 Dec;21(4):250-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GNAq mutations are not identified in papillary thyroid carcinomas and hyperfunctioning thyroid nodules.
  • Since these neoplasms share with thyroid carcinomas a high frequency of MAP kinase pathway-activating mutations, we hypothesized whether GNAq mutations could also play a role in the development of thyroid carcinomas.
  • Additionally, activating mutations of another subtype of G protein (GNAS1) are frequently found in hyperfunctioning thyroid adenomas, making it plausible that GNAq-activating mutations could also be found in some of these nodules.
  • To investigate thyroid papillary carcinomas and thyroid hyperfunctioning nodules for GNAq mutations in exon 5, codon 209, a total of 32 RET/PTC, BRAF, and RAS negative thyroid papillary carcinomas and 13 hyperfunctioning thyroid nodules were evaluated.
  • Although plausible, GNAq mutations seem not to play an important role in the development of thyroid follicular neoplasms, either benign hyperfunctioning nodules or malignant papillary carcinomas.
  • Our results are in accordance with the literature, in which no GNAq hotspot mutations were found in thyroid papillary carcinomas, as well as in an extensive panel of other tumors.
  • The molecular basis for MAP-kinase pathway activation in RET-PTC/BRAF/RAS negative thyroid carcinomas remains to be determined.
  • [MeSH-major] Adenoma / genetics. Carcinoma, Papillary / genetics. GTP-Binding Protein alpha Subunits / genetics. Mutation. Thyroid Neoplasms / genetics. Thyroid Nodule / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2004 Sep;36(9):961-8 [15322542.001]
  • [Cites] Genomics. 1995 Dec 10;30(3):470-75 [8825633.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5230-4 [18719078.001]
  • [Cites] Nature. 1989 Aug 31;340(6236):692-6 [2549426.001]
  • [Cites] PLoS One. 2009 Aug 31;4(8):e6833 [19718445.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Dec;82(12):4184-8 [9398737.001]
  • [Cites] J Biol Chem. 1992 Sep 15;267(26):18263-6 [1526966.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):599-602 [19078957.001]
  • [Cites] Mol Cell Biol. 1992 Oct;12(10):4687-93 [1328859.001]
  • [Cites] Acta Oncol. 2009;48(7):1082-4 [19551532.001]
  • [Cites] Thyroid. 2009 Aug;19(8):921-2 [19445628.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):292-306 [16557281.001]
  • (PMID = 20714830.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GNAQ protein, human; 0 / GTP-Binding Protein alpha Subunits; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gq-G11
  •  go-up   go-down


55. Raggio E, Camandona M, Solerio D, Martino P, Franchello A, Orlandi F, Gasparri G: The diagnostic accuracy of the immunocytochemical markers in the pre-operative evaluation of follicular thyroid lesions. J Endocrinol Invest; 2010 Jun;33(6):378-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic accuracy of the immunocytochemical markers in the pre-operative evaluation of follicular thyroid lesions.
  • Aim of the study was to consider the diagnostic accuracy of galectine-3 (GAL3) in the pre-operative cytological evaluation of follicular lesions.
  • MATERIALS AND METHODS: We retrospectively evaluated 100 patients suffering from thyroid nodular disease submitted to thyroidectomy from 2006 to 2007 in our Institution.
  • Based on preoperative cytological reports, 40 patients had pre-operative malignant results, and 60 patients (46 females and 14 males) showed follicular lesions.
  • The GAL3 expression in neoplastic and benign lesions was significantly different (GAL3+ in 16 out of 29 neoplastic lesions, GAL3+ 0 out of 31 benign lesions, p<0.01).
  • Even comparing the GAL3 positivity between the follicular adenomas (0 GAL3+ out of 20) and the group of follicular carcinomas (5 GAL3+ out of 6), we found a statistically significant difference (p<0.01).
  • CONCLUSIONS: Based on the data from our experience, the patients with a cytological diagnosis of GAL3 positive follicular neoformation should be referred for surgery without any further immunocytological testing.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Galectin 3 / analysis. Thyroid Neoplasms / diagnosis. Thyroid Nodule / diagnosis
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / surgery. Biomarkers / analysis. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Diagnostic Errors. Female. Gene Expression. Humans. Keratin-19 / biosynthesis. Male. Middle Aged. Predictive Value of Tests. Preoperative Care. Retrospective Studies. Sensitivity and Specificity. Thyroid Gland / chemistry. Thyroid Gland / surgery

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Langenbecks Arch Surg. 2004 Jun;389(3):193-7 [15107999.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):950; author reply 950-1 [12574240.001]
  • [Cites] Cancer Lett. 2003 Mar 10;191(2):223-7 [12618337.001]
  • [Cites] Mayo Clin Proc. 1994 Jan;69(1):44-9 [8271850.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):815-22 [7677193.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):305-17 [15947105.001]
  • [Cites] Endocrinol Metab Clin North Am. 1995 Dec;24(4):663-710 [8608777.001]
  • [Cites] Diagn Cytopathol. 2002 Jan;26(1):41-4 [11782086.001]
  • [Cites] J Pathol. 1997 Jan;181(1):80-6 [9072007.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):529-34 [7725740.001]
  • [Cites] Diagn Cytopathol. 1998 Feb;18(2):93-7 [9484636.001]
  • [Cites] Arch Pathol Lab Med. 2003 May;127(5):579-83 [12708901.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):696-702 [11710686.001]
  • [Cites] Endocr Pathol. 2001 Fall;12(3):255-7 [11740046.001]
  • [Cites] Acta Cytol. 1997 May-Jun;41(3):687-91 [9167684.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17 ):1764-71 [15496625.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):553-9 [8426623.001]
  • [Cites] Am J Med. 1994 Aug;97(2):152-7 [8059781.001]
  • (PMID = 19625759.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Keratin-19
  •  go-up   go-down


56. Lozano-Gómez MJ, Sánchez-Blanco JM, Vázquez-Morón M, Parra-Membrives P, Torres-Arcos C, Jurado-Jiménez R, Gómez-Rubio D, Recio-Moyano G: [Hemithyroidectomy in a unilateral goiter: a valid therapeutic option. Review of the contralateral hemithyroid ten years after treatment]. Cir Esp; 2006 Jul;80(1):23-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study was to evaluate the remaining thyroid in patients with NG compared with those with follicular adenoma who underwent hemithyroidectomy.
  • PATIENTS AND METHODS: Patients who underwent surgery for unilateral NG with over 10 years of postoperative follow-up and normal findings on ultrasonography of the contralateral thyroid lobe were selected to form the study group (SG).
  • Patients with follicular adenoma (with normal contralateral ultrasonography) who underwent hemithyroidectomy during the same period were selected to form the control group (CG).
  • Ultrasonographic nodules were found in the remaining thyroid lobe in 70% of patients in the SG and in 60% of those in the CG, with no statistically significant differences.
  • CONCLUSIONS: After hemithyroidectomy, both groups of patients developed nodules in the remaining thyroid lobe, with no statistically significant differences.
  • [MeSH-major] Goiter, Nodular / surgery. Thyroid Gland / pathology. Thyroidectomy / methods

  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16796949.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


57. Norman J, Politz D: 5,000 parathyroid operations without frozen section or PTH assays: measuring individual parathyroid gland hormone production in real time. Ann Surg Oncol; 2009 Mar;16(3):656-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5,000 parathyroid operations without frozen section or PTH assays: measuring individual parathyroid gland hormone production in real time.
  • Patients who had a frozen section were not included; the removal of parathyroid glands was determined solely by the physiologic activity of each gland as determined by contained radioactivity.
  • Ex vivo measurements of parathyroid glands, thyroid nodules, lymph nodes, thymus, and fat were obtained from all patients, constituting >32,000 specimens.
  • Adenomas (n=5,120) contained 57+/-38% of background radioactivity; hyperplastic glands (n=640) contained 16+/-4%; and normal glands (n=9,400) contained 4+/-0.1% (all p<0.00001).
  • The initial cure rate was 99.23% with missed contralateral second adenomas causing all failures (subsequently cured).
  • CONCLUSIONS: Measures of sequestered radioactivity is an extremely accurate estimate of individual parathyroid gland hormone production allowing near 100% distinction between normal, hyperplasic, and adenomatous glands as well as distinguishing parathyroids from other neck tissues (fat, lymph nodes, thyroid).
  • [MeSH-major] Adenoma / surgery. Hyperparathyroidism, Primary / surgery. Parathyroid Hormone / blood. Parathyroid Neoplasms / surgery. Parathyroidectomy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Diagnosis, Differential. Female. Follow-Up Studies. Frozen Sections. Humans. Hyperplasia / diagnosis. Hyperplasia / radionuclide imaging. Lymph Nodes / pathology. Male. Middle Aged. Prognosis. Prospective Studies. Radiopharmaceuticals. Technetium Tc 99m Sestamibi. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19130135.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


58. Takei H, Buckleair L, Goodman JC, Powell SZ: Intraoperative cytologic diagnosis of symptomatic carcinoma (pulmonary small cell carcinoma) metastatic to the pituitary gland: a case report. Acta Cytol; 2007 Jul-Aug;51(4):637-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative cytologic diagnosis of symptomatic carcinoma (pulmonary small cell carcinoma) metastatic to the pituitary gland: a case report.
  • BACKGROUND: Carcinoma metastatic to the pituitary gland is infrequent and has been reportedly detected in approximately 1% of pituitary surgical cases.
  • It may masquerade as a pituitary adenoma both clinically and radiologically.
  • The initial radiologic diagnosis based on magnetic resonance imaging was pituitary adenoma.
  • While intraoperative frozen section examination could not completely exclude an "atypical" pituitary adenoma, cytologic touch imprint findings were diagnostic of metastatic small cell carcinoma.
  • CONCLUSION: For intraoperative diagnosis at the time ofpituitary surgery, cytologic imprints can be used reliably to make a diagnosis not only of pituitary adenoma but also of metastatic lesions.
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Lung Neoplasms / diagnosis. Pituitary Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17718143.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


59. Zablotska LB, Bogdanova TI, Ron E, Epstein OV, Robbins J, Likhtarev IA, Hatch M, Markov VV, Bouville AC, Olijnyk VA, McConnell RJ, Shpak VM, Brenner A, Terekhova GN, Greenebaum E, Tereshchenko VP, Fink DJ, Brill AB, Zamotayeva GA, Masnyk IJ, Howe GR, Tronko MD: A cohort study of thyroid cancer and other thyroid diseases after the Chornobyl accident: dose-response analysis of thyroid follicular adenomas detected during first screening in Ukraine (1998-2000). Am J Epidemiol; 2008 Feb 1;167(3):305-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A cohort study of thyroid cancer and other thyroid diseases after the Chornobyl accident: dose-response analysis of thyroid follicular adenomas detected during first screening in Ukraine (1998-2000).
  • The Chornobyl (Chernobyl) accident in 1986 exposed many individuals to radioactive iodines, chiefly (131)I, the effects of which on benign thyroid diseases are largely unknown.
  • To investigate the risk of follicular adenoma in relation to radiation dose after Chornobyl, the authors analyzed the baseline data from a prospective screening cohort study of those exposed as children or adolescents.
  • A stratified random sample was selected from all individuals who were younger than 18 years, had thyroid radioactivity measurements taken within 2 months after the accident, and resided in the three heavily contaminated areas in Ukraine.
  • This analysis is based on the 23 cases diagnosed in 12,504 subjects for whom personal history of thyroid diseases was known.
  • In conclusion, persons exposed to radioactive iodines as children and adolescents have an increased risk of follicular adenoma, though it is smaller than the risk of thyroid cancer in the same cohort.
  • [MeSH-major] Adenoma / etiology. Neoplasms, Radiation-Induced / epidemiology. Thyroid Neoplasms / etiology


60. Cerutti JM, Latini FR, Nakabashi C, Delcelo R, Andrade VP, Amadei MJ, Maciel RM, Hojaij FC, Hollis D, Shoemaker J, Riggins GJ: Diagnosis of suspicious thyroid nodules using four protein biomarkers. Clin Cancer Res; 2006 Jun 1;12(11 Pt 1):3311-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of suspicious thyroid nodules using four protein biomarkers.
  • PURPOSE: Fine-needle aspiration (FNA) cytology, a standard method for thyroid nodule diagnosis, cannot distinguish between benign follicular thyroid adenoma (FTA) and malignant follicular thyroid carcinoma (FTC).
  • The goal of this study was to determine if antibody markers used alone or in combination could accurately distinguish between a wider variety of benign and malignant thyroid lesions in fixed sections and FNA samples.
  • EXPERIMENTAL DESIGN: Immunohistochemistry was done on 27 FTA, 25 FTC, and 75 other benign and malignant thyroid tissue sections using custom antibodies for chromosome 1 open reading frame 24 (C1orf24) and integral membrane protein 1 (ITM1) and commercial antibodies for DNA damage-inducible transcript 3 (DDIT3) and arginase II (ARG2).
  • RNA expression was measured by quantitative PCR in 33 thyroid lesions.
  • CONCLUSIONS: We improved this diagnostic test by adding C1orf24 and ITM1 custom antibodies and showing use on a wider variety of thyroid pathology.
  • Use of one or more of these antibodies should improve diagnostic accuracy of suspicious thyroid nodules from both tissue sections and FNA samples.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenoma / diagnosis. Biomarkers, Tumor / analysis. Immunohistochemistry / methods. Thyroid Neoplasms / diagnosis. Thyroid Nodule / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740752.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA113461; United States / PHS HHS / / S98-146
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / DDIT3 protein, human; 0 / FAM129A protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 147336-12-7 / Transcription Factor CHOP; EC 2.4.1.- / Hexosyltransferases; EC 2.4.99.18 / STT3A protein, human; EC 3.5.3.1 / Arginase; EC 3.5.3.1 / arginase II, human
  •  go-up   go-down


61. Liu YY, Morreau H, Kievit J, Romijn JA, Carrasco N, Smit JW: Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol; 2008 Mar;158(3):375-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma.
  • OBJECTIVES: The microscopic distinction between benign and malignant thyroid lesions in clinical practice is still largely based on conventional histology.
  • This study was performed to evaluate the diagnostic value of galectin-3 (Gal-3), Hector Battifora mesothelial-1 (HBME-1), cytokeratin (CK)-19, CBP P300-interacting transactivator with glutamic acid E- and aspartic acid D-rich C-terminal domain (CITED-1), fibronectin (FN)-1, peroxisome proliferator-activated receptor (PPAR)-gamma, and intracellular sodium/iodide symporter (iNIS) immunostaining in a large panel of thyroid neoplasms.
  • METHODS: We used tissue arrays containing 177 thyroid tissues: 100 benign tissues (including normal thyroid, Graves disease, multinodular goiter, and follicular adenoma (FA)) and 77 thyroid carcinomas (including papillary thyroid carcinoma (PTC), follicular thyroid carcinoma, and follicular variant of PTC (FVPTC)).
  • RESULTS: In general, we found overexpression of FN-1, CITED-1, Gal-3, CK-19, HBME-1, and iNIS in malignant thyroid lesions.
  • Gal-3, FN-1, and iNIS had the highest accuracy in the differential diagnosis of follicular lesions.
  • A panel of Gal-3, FN-1, and iNIS, identified by hierarchical cluster analysis, had a 98% accuracy to differentiate between FA and malignant thyroid lesions.
  • CONCLUSION: We conclude that identifying optimal antibody panels with cluster analysis increases the diagnostic value in the differential diagnosis of thyroid neoplasms, the combination of FN-1, Gal-3, and iNIS having the best accuracy (98%).

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18299472.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / CITED1 protein, human; 0 / Fibronectins; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Keratin-19; 0 / Nuclear Proteins; 0 / PPAR gamma; 0 / Symporters; 0 / Transcription Factors; 0 / sodium-iodide symporter
  •  go-up   go-down


62. Banito A, Pinto AE, Espadinha C, Marques AR, Leite V: Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours. Clin Endocrinol (Oxf); 2007 Nov;67(5):706-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.
  • OBJECTIVE: Follicular thyroid tumours present several genetic alterations such as aneuploidy, RAS mutations and PAX8/PPARgammarearrangements.
  • The aim of our study was to investigate the correlation between aneuploidy, RAS mutations and PAX8/PPARgamma gene rearrangement in thyroid follicular tumours.
  • DESIGN: Ploidy status was determined by flow cytometry in 111 thyroid lesions (42 follicular thyroid adenomas, 27 follicular thyroid carcinomas, 19 follicular variants of papillary thyroid carcinoma, 20 poorly differentiated thyroid carcinomas and 3 anaplastic thyroid carcinomas).
  • The aneuploid tumours harbouring RAS mutations were two poorly differentiated carcinomas and one follicular variant of papillary thyroid carcinoma with poorly differentiated areas.
  • Three of five (60%) follicular thyroid adenomas and 1 of 7 (14%) follicular thyroid carcinomas, with the PAX8/PPARgamma fusion gene, were aneuploid.
  • CONCLUSIONS: Our data suggest that aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenoma / genetics. Aneuploidy. Genes, ras. Point Mutation. Thyroid Neoplasms / genetics
  • [MeSH-minor] Carcinoma / genetics. Carcinoma, Papillary, Follicular / genetics. DNA Mutational Analysis. Flow Cytometry. Gene Rearrangement. Humans. Oncogene Proteins, Fusion. PPAR gamma / genetics. Paired Box Transcription Factors / genetics. Statistics as Topic

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17651453.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors
  •  go-up   go-down


63. Asioli S, Bussolati G: Emerin immunohistochemistry reveals diagnostic features of nuclear membrane arrangement in thyroid lesions. Histopathology; 2009 Apr;54(5):571-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerin immunohistochemistry reveals diagnostic features of nuclear membrane arrangement in thyroid lesions.
  • AIMS: Objective appreciation of irregularities of the nuclear shape is a key parameter in the diagnosis of thyroid lesions, since foldings of the nuclear membrane (NM) featuring indentations, grooves and pseudoinclusions characterize papillary thyroid carcinomas (PTC).
  • METHODS AND RESULTS: Immunohistochemistry of the NM with emerin as well as three-dimensional reconstruction of the images (through deconvolution processing) performed on a series of 54 cases (processed following the tissue array procedure) revealed a uniform arrangement of the NM in non-neoplastic lesions (thyroiditis, microfollicular goitre, follicular adenoma) and normal thyroid as well as in follicular carcinoma.
  • CONCLUSIONS: Decoration of the NM represents an original approach to identify PTC nuclear shape, highlights new structural features and might be helpful in the differential diagnosis between so-called nuclear pseudoinclusions and artefactual 'bubbles'.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Nuclear Envelope / pathology. Thyroid Diseases / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Fluorescent Antibody Technique. Humans. Image Interpretation, Computer-Assisted. Immunohistochemistry. Membrane Proteins. Nuclear Proteins. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302538.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Nuclear Proteins; 0 / emerin
  •  go-up   go-down


64. Guerra LN, Miler EA, Moiguer S, Karner M, Orlandi AM, Fideleff H, Burdman JA: Telomerase activity in fine needle aspiration biopsy samples: application to diagnosis of human thyroid carcinoma. Clin Chim Acta; 2006 Aug;370(1-2):180-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase activity in fine needle aspiration biopsy samples: application to diagnosis of human thyroid carcinoma.
  • BACKGROUND: The diagnosis of thyroid follicular carcinoma by fine needle aspiration biopsy is a well known problem in thyroid pathology.
  • METHODS: We evaluated telomerase activity (TA) in 85 fine needle aspiration biopsy (FNAB) samples from patients with thyroid nodules.
  • Surgery samples from patients with tumor or follicular adenomas were also analyzed.
  • Among them, 4 follicular carcinomas and 1 papillary carcinoma were labeled as indeterminate by FNAB cytological examination.
  • FNAB samples from follicular adenomas were diagnosed as indeterminate by cytological examination, but they showed no detectable TA.
  • Tumor tissues from patients with follicular or papillary thyroid carcinomas presented TA >10 Units, whereas follicular adenoma tissues (benign nodules) showed no TA.
  • CONCLUSION: Our results showed a good correlation between TA in FNAB samples and tumor/nodule thyroid tissue.
  • This suggested that use of TA as a biological marker of malignancy might be a useful tool in the diagnosis of follicular thyroid carcinomas or follicular thyroid adenomas using FNAB samples.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Telomerase / metabolism. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Chim Acta. 2007 Sep;384(1-2):188
  • (PMID = 16600201.001).
  • [ISSN] 0009-8981
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


65. Drieschner N, Belge G, Rippe V, Meiboom M, Loeschke S, Bullerdiek J: Evidence for a 3p25 breakpoint hot spot region in thyroid tumors of follicular origin. Thyroid; 2006 Nov;16(11):1091-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for a 3p25 breakpoint hot spot region in thyroid tumors of follicular origin.
  • Epithelial tumors of the thyroid are cytogenetically well-investigated tumors.
  • Recently, we have been able to describe the involvement of a novel gene called THADA in benign thyroid lesions with 2p21 rearrangements.
  • Other fusion genes found in thyroid lesions are RET/PTC and PAX8/PPAR(gamma).
  • The latter occurs in follicular thyroid carcinomas with a t(2;3)(q13;p25).
  • Here we present molecular-cytogenetic and cytogenetic investigations on a follicular thyroid adenoma with a t(2;20;3)(p21;q11.2; p25).
  • Our findings suggest that the close surrounding of PPAR(gamma) is a breakpoint hot spot region, leading to recurrent alterations of this gene in thyroid tumors of follicular origin including carcinomas as well as adenomas with or without involvement of PAX8.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Chromosome Breakage. Neoplasm Proteins / genetics. PPAR gamma / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17123335.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / PPAR gamma; 0 / THADA protein, human
  •  go-up   go-down


66. Keskek M, Ocak S, Ozalp N, Koc M, Tez M: Clinical significance of Hürthle cells in fine needle aspiration biopsy for multinodular goitre. Endocr Regul; 2010 Apr;44(2):65-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: So far, the significance of Hürthle cell predominance in fine needle aspiration biopsy (FNAB) in multinodular goitre (MNG) appears not definitely clarified.
  • The aim of this study was to determine if there are any clinical factors that can be used to distinguish either malignant or benign disease with the aid of FNAB specimen that contains a predominance of Hürthle cells in multinodular goitre patients.
  • In 37 (9% of them) the FNAB specimen was interpreted as consistent with a Hürthle cell lesion.
  • RESULTS: Among 37 patients with Hürthle cell predominance in FNAB, 29 had benign diseases and 8 had malignant diseases resulting in 21.6% prevalence of malignancy.
  • There were no differences in age, sex, functional status of the thyroid gland, and nodule size between patients with benign versus malignant disease.
  • CONCLUSION: Total thyroidectomy should be recommended for all multinodular goitre patients with Hürthle cell predominance in FNAB, since there is no preoperative predictor of malignancy in these cases.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Biopsy, Fine-Needle. Goiter, Nodular / pathology. Oxyphil Cells / pathology. Thyroid Gland / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20429635.001).
  • [ISSN] 1210-0668
  • [Journal-full-title] Endocrine regulations
  • [ISO-abbreviation] Endocr Regul
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


67. Turnbull MM, Humeniuk V, Stein B, Suthers GK: Arteriovenous malformations in Cowden syndrome. J Med Genet; 2005 Aug;42(8):e50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical features include trichilemmomas, verrucose lesions of the skin, macrocephaly, intellectual disability, cerebellar gangliocytoma, thyroid adenomas, fibroadenomas of the breast, and hamartomatous colonic polyps.
  • A family is described with a clinical diagnosis of Cowden syndrome, a familial frameshift mutation in the PTEN gene, and large visceral arteriovenous malformations.
  • Recognition of arteriovenous malformations as a clinical feature of Cowden syndrome has implications for the clinical management of patients with this disorder.
  • [MeSH-major] Arteriovenous Malformations / diagnosis. Hamartoma Syndrome, Multiple / diagnosis

  • Genetic Alliance. consumer health - Cowden Syndrome.
  • MedlinePlus Health Information. consumer health - Arteriovenous Malformations.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061556.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] eng
  • [Databank-accession-numbers] OMIM/ 153480/ 158350
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC1736111
  •  go-up   go-down


68. Del Monte P, Bernasconi D, Ruelle A, Marugo A, Marugo M, Torre R: [Effect of long-term treatment with octreotide-lar in a TSH-secreting pituitary macroadenoma and secondary hyperthyroidism]. Minerva Endocrinol; 2005 Jun;30(2):95-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thyroid function evaluation showed secondary hyperthyroidism, with high free thyroid hormone levels and TSH inappropriately in the high-normal range (4.2 mU/ml), only slightly responsive to TRH-stimulation (6 microU/ml).
  • Thyroid autoimmunity tests were negative and ultrasonography evidenced a diffusely enlarged gland.
  • The patient underwent transphenoidal adenomectomy, and immunohistochemistry confirmed the diagnosis of a TSH-secreting pituitary macroadenoma.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Hyperthyroidism / drug therapy. Hyperthyroidism / etiology. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy. Thyrotropin / secretion
  • [MeSH-minor] Aged. Humans. Male. Thyroid Hormones / blood. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15988405.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Thyroid Hormones; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


69. Vetshev PS, Chilingaridi KE, Gabaidze DI, Saliba MB: [Adenomas of the thyroid gland]. Khirurgiia (Mosk); 2005;(7):4-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomas of the thyroid gland].
  • Different methods of diagnosis and treatment of thyroid gland's adenomas are analyzed.
  • When elective histological examination reveals thyroid cancer, reoperation is not necessary.
  • The groups of patients with confirmed diagnosis "thyroid adenoma" and high cancer risk were distinguished.
  • Optimization of differential diagnosis of thyroid adenoma and cancer based on cytological and immunogenotypic tests will help determine indications to surgical treatment in adequate scope.
  • [MeSH-major] Adenoma. Thyroid Neoplasms. Thyroidectomy / methods
  • [MeSH-minor] Biopsy, Needle. Diagnosis, Differential. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16091687.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 28
  •  go-up   go-down


70. Peverelli E, Mantovani G, Bondioni S, Pellegrini C, Bosari S, Lania AG, Beck-Peccoz P, Spada A: Expression of the two alternatively spliced PRKAR1A RNAs in human endocrine glands. Mol Cell Endocrinol; 2005 Jun 30;238(1-2):51-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Heterozygous loss of function mutations in human PKAR1A gene (PRKAR1A) have been identified in patients with Carney complex (CNC), an autosomal dominant familial multiple neoplasia syndrome displaying different endocrine tumors, including adrenocortical tumors, GH-secreting pituitary tumors and thyroid adenomas.
  • In order to investigate the relative expression of the two mRNA transcripts (1a and 1b) in human adult endocrine tissues involved in the determination of CNC phenotype, we selected 17 pituitary, 20 adrenal and seven thyroid tissues from tumoral and peri-tumoral lesion samples.
  • This study first reports that human pituitary and thyroid tissues show a similar expression of the two transcripts, whereas in adrenal tissues transcript 1b is the most abundant one.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Gene Expression Regulation, Neoplastic / genetics. Pituitary Neoplasms / genetics. Proteins / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / metabolism. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921845.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; 0 / PRKAR1A protein, human; 0 / Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases
  •  go-up   go-down


71. Foukakis T, Au AY, Wallin G, Geli J, Forsberg L, Clifton-Bligh R, Robinson BG, Lui WO, Zedenius J, Larsson C: The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion. J Clin Endocrinol Metab; 2006 Mar;91(3):1143-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion.
  • NORE1A has not been studied in thyroid cancer.
  • OBJECTIVE: The objective of this study was to investigate whether NORE1A is involved in follicular thyroid cancer (FTC) development.
  • DESIGN: We analyzed NORE1A expression in 25 FTCs, eight follicular thyroid adenomas, and seven normal thyroid tissues by TaqMan quantitative RT-PCR.
  • No NORE1A promoter methylation was detected in the 32 thyroid tumors analyzed.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Monomeric GTP-Binding Proteins / genetics. PPAR gamma / genetics. Paired Box Transcription Factors / genetics. RNA, Messenger / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Breast Neoplasms. Cell Line, Tumor. DNA Methylation. DNA Mutational Analysis. DNA, Neoplasm / genetics. Exons. Female. Gene Expression Regulation, Neoplastic. Genes, Reporter. Humans. Promoter Regions, Genetic. Recombination, Genetic. Restriction Mapping. Reverse Transcriptase Polymerase Chain Reaction. Suppression, Genetic / genetics. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352687.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors; 0 / RASSF5 protein, human; 0 / RNA, Messenger; EC 3.6.5.2 / Monomeric GTP-Binding Proteins
  •  go-up   go-down


72. Yegen G, Demir MA, Ertan Y, Nalbant OA, Tunçyürek M: Can CD10 be used as a diagnostic marker in thyroid pathology? Virchows Arch; 2009 Jan;454(1):101-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can CD10 be used as a diagnostic marker in thyroid pathology?
  • CD10-common acute lymphoblastic leukemia antigen is a membrane-bound zinc metalloproteinase that is expressed by different hematopoietic cell types at unique stages of lymphoid and myeloid differentiation.
  • Recently, it has been found to be useful in the differential diagnosis of benign and malignant follicular-patterned lesions of the thyroid.
  • In the present study, we evaluated the staining pattern of CD10 in various thyroid lesions, including 14 benign and 61 malignant cases, as well as in adjacent thyroid tissue.
  • CD10 was negative in normal thyroid tissue, adenomatous nodules, minimally invasive follicular carcinoma, and well-differentiated carcinoma.
  • It was expressed in nine of 14 (64.2%) conventional papillary carcinomas, four of 24 (16.6%) follicular variant of papillary carcinomas, three of six (50%) papillary microcarcinomas, one of nine (11.1%) widely invasive follicular carcinomas, and three of ten (30%) follicular adenomas.
  • In contrast to results of previous studies, CD10 is not useful in the classification of thyroid follicular lesions as benign or malignant, but it shows strong positivity in conventional papillary carcinoma.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / metabolism. Neprilysin / metabolism. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / metabolism. Adenoma / pathology. Diagnosis, Differential. Humans. Retrospective Studies. Sensitivity and Specificity. Thyroid Gland / metabolism. Thyroid Gland / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thyroid. 2003 Mar;13(3):291-5 [12729479.001]
  • [Cites] Hum Pathol. 2003 Nov;34(11):1092-100 [14652809.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1336-40 [15371949.001]
  • [Cites] In Vivo. 2004 Mar-Apr;18(2):189-95 [15113046.001]
  • [Cites] Am J Pathol. 1989 May;134(5):961-5 [2541615.001]
  • [Cites] Histopathology. 2002 Sep;41(3):236-43 [12207785.001]
  • [Cites] Cancer. 1984 Aug 1;54(3):535-40 [6733684.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2745-52 [12788883.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):143-50 [11789719.001]
  • [Cites] Int J Surg Pathol. 2000 Jul;8(3):181-183 [11493987.001]
  • [Cites] Am J Surg. 2004 Nov;188(5):459-62 [15546550.001]
  • [Cites] J Clin Pathol. 1999 Nov;52(11):849-50 [10690178.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):183-8 [15252732.001]
  • [Cites] Head Neck. 2004 Nov;26(11):960-6 [15386597.001]
  • [Cites] Nature. 1980 Feb 7;283(5747):583-5 [6928257.001]
  • [Cites] Blood. 1993 Aug 15;82(4):1052-70 [8102558.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3494-502 [10550147.001]
  • (PMID = 19031085.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


73. Betal D, Babu R, Mehmet V: Monophasic synovial sarcoma of the pharynx: a case report. Int Semin Surg Oncol; 2009;6:9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a case of a 62 year-old male presenting with a left thyroid lump initially though to be a thyroid adenoma but subsequently diagnosed as a monophasic synovial sarcoma of the pharynx.
  • We discuss the diagnosis and treatment of this case.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plast Reconstr Surg. 1965 Sep;36(3):325-9 [4284063.001]
  • [Cites] Arch Pathol Lab Med. 2008 Apr;132(4):698-702 [18384223.001]
  • [Cites] J Med Case Rep. 2008;2:18 [18218098.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1173-80 [17689031.001]
  • [Cites] Ann Surg. 1914 Oct;60(4):440-50 [17863247.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2007 Aug;13(4):258-61 [17717503.001]
  • [Cites] Head Neck. 2007 Aug;29(8):731-40 [17274049.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):105-13 [17592298.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):946-9 [17509396.001]
  • [Cites] Histopathology. 2007 Mar;50(4):521-3 [17448034.001]
  • [Cites] Gynecol Oncol. 2006 Feb;100(2):433-6 [16226798.001]
  • [Cites] Arch Pathol Lab Med. 2005 Aug;129(8):1047-9 [16048399.001]
  • [Cites] Clin Neurol Neurosurg. 1996 Aug;98(3):249-52 [8884099.001]
  • [Cites] J Laryngol Otol. 1995 Dec;109(12):1207-10 [8551160.001]
  • [Cites] Radiother Oncol. 1994 Oct;33(1):23-30 [7878206.001]
  • [Cites] J Laryngol Otol. 1983 Dec;97(12):1173-6 [6315842.001]
  • [Cites] J Bone Joint Surg Am. 1982 Jan;64(1):112-22 [6274877.001]
  • [Cites] Spine (Phila Pa 1976). 2001 Feb 1;26(3):310-3 [11224869.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1238-47 [11230464.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):776-81 [11395555.001]
  • [Cites] Ear Nose Throat J. 2002 Jan;81(1):36-9 [11816387.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2002 Mar 15;63(1):61-5 [11879931.001]
  • [Cites] Oncology. 2003;65 Suppl 2:80-4 [14586155.001]
  • [Cites] Pathol Res Pract. 2003;199(12):827-33 [14989495.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2004 Feb;24(1):33-6 [15270432.001]
  • [Cites] Ann Oncol. 2009 Mar;20(3):425-30 [19088169.001]
  • (PMID = 19335917.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2670314
  •  go-up   go-down


74. Jabbour SA, Davidovici BB, Wolf R: Rare syndromes. Clin Dermatol; 2006 Jul-Aug;24(4):299-316
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermatologists may also encounter patients presenting with skin lesions that reflect an underlying endocrine disorder not commonly seen in daily practice.
  • Multiple endocrine neoplasia type 2A is characterized by medullary thyroid cancer, pheochromocytoma, and primary parathyroid hyperplasia.
  • Multiple endocrine neoplasia type 2B is characterized by medullary thyroid cancer and pheochromocytoma but not hyperparathyroidism.
  • Multiple endocrine neoplasia type 1 is an autosomal dominant predisposition to tumors of the parathyroid glands (four-gland hyperplasia), anterior pituitary, and pancreatic islet cells; hence, the mnemonic device of the "3 Ps"; multiple cutaneous lesions (angiofibromas and collagenomas) are frequent in patients with multiple endocrine neoplasia type 1.
  • Carney complex may be viewed as a form of multiple endocrine neoplasia because affected patients often have tumors of two or more endocrine glands, including primary pigmented nodular adrenocortical disease (some with Cushing's syndrome), pituitary adenoma, testicular neoplasms, thyroid adenoma or carcinoma, and ovarian cysts.
  • Additional unusual manifestations include psammomatous melanotic schwannoma, breast ductal adenoma, and a rare bone tumor, osteochondromyxoma.
  • Mast cell diseases include all disorders of mast cell proliferation.

  • MedlinePlus Health Information. consumer health - Endocrine Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16828412.001).
  • [ISSN] 0738-081X
  • [Journal-full-title] Clinics in dermatology
  • [ISO-abbreviation] Clin. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 155
  •  go-up   go-down


75. Jung CK, Lee A, Jung ES, Choi YJ, Jung SL, Lee KY: Split sample comparison of a liquid-based method and conventional smears in thyroid fine needle aspiration. Acta Cytol; 2008 May-Jun;52(3):313-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Split sample comparison of a liquid-based method and conventional smears in thyroid fine needle aspiration.
  • OBJECTIVE: To compare the efficacy of the SurePath (SP) vs. conventional smears (CS) in fine needle aspiration (FNA) of thyroid gland lesions.
  • STUDY DESIGN: A total of 193 FNA cases with thyroid nodules were studied.
  • The diagnostic categories of unsatisfactory, benign, atypical and malignant were compared.
  • On SP slides, nuclear detail and nucleoli were more easily detected and nuclear irregularity was very useful for the diagnosis of papillary carcinoma.
  • The overall sensitivity of FNA in diagnosing thyroid neoplasm was 90.9% for CS and 93.9% for SP.
  • [MeSH-major] Biopsy, Fine-Needle. Specimen Handling / methods. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Female. Galectin 3 / metabolism. Humans. Hyperplasia. Immunohistochemistry. Male. Middle Aged. Retrospective Studies. Staining and Labeling. Thyroid Nodule / diagnosis. Thyroid Nodule / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540296.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Galectin 3
  •  go-up   go-down


76. Abdel Khalek M, Zhong X, Moroz K, Kandil E: Kikuchi disease and thyroid follicular adenoma. Ear Nose Throat J; 2010 Sep;89(9):412-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kikuchi disease and thyroid follicular adenoma.
  • [MeSH-major] Adenoma / complications. Histiocytic Necrotizing Lymphadenitis / complications. Thyroid Neoplasms / complications
  • [MeSH-minor] Adult. Female. Humans. Lupus Erythematosus, Systemic / complications. Lymph Nodes / pathology. Neck / radiography. Thyroid Gland / radiography. Thyroid Gland / surgery. Thyroidectomy. Tomography, X-Ray Computed. Trachea / radiography

  • Genetic Alliance. consumer health - Kikuchi disease.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ear Nose Throat J. 2010 Oct;89(10):486. Khalek, Mohamed Abdel [corrected to Abdel Khalek, Mohamed]
  • (PMID = 20859864.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Anderson L, Middleton WD, Teefey SA, Reading CC, Langer JE, Desser T, Szabunio MM, Mandel SJ, Hildebolt CF, Cronan JJ: Hashimoto thyroiditis: Part 2, sonographic analysis of benign and malignant nodules in patients with diffuse Hashimoto thyroiditis. AJR Am J Roentgenol; 2010 Jul;195(1):216-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hashimoto thyroiditis: Part 2, sonographic analysis of benign and malignant nodules in patients with diffuse Hashimoto thyroiditis.
  • OBJECTIVE: The purpose of this article is to compare sonographic features of benign and malignant nodules in patients with diffuse Hashimoto thyroiditis.
  • SUBJECTS AND METHODS: As part of an ongoing multiinstitutional study, patients who underwent ultrasound and fine-needle aspiration of one or more thyroid nodules were analyzed for a variety of predetermined sonographic features.
  • Patients with a sonographic appearance consistent with diffuse Hashimoto thyroiditis and with coexisting nodules that could be confirmed to be benign or malignant by fine-needle aspiration or surgical pathologic analysis were included in the study.
  • RESULTS: Among nodules within diffuse Hashimoto thyroiditis, 84% (69/82) were benign (35 nodular Hashimoto thyroiditis, 32 nodular hyperplasia, and two follicular adenoma), and 16% (13/82) were malignant (12 papillary carcinoma and one lymphoma).
  • Benign nodules were more likely to be hyperechoic (46% vs 9%), to have a halo (39% vs 15%), and to lack calcifications (88% vs 23%).
  • Benign nodules more often had ill-defined margins (36% vs 8%).
  • CONCLUSION: Sonographic features of benign and malignant nodules within diffuse Hashimoto thyroiditis are generally similar to the features typical of benign and malignant nodules in the general population.
  • [MeSH-major] Hashimoto Disease / ultrasonography. Thyroid Neoplasms / ultrasonography. Thyroid Nodule / ultrasonography. Ultrasonography, Doppler / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hashimoto's Disease.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20566819.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


78. Wasko R, Michalek K, Pacholska J, Obrepalska-Steplowska A, Gozdzicka-Jozefiak A, Sowinski J: Clinical significance of the insulin-like growth factor I gene promoter (P1) polymorphism in thyroid nodular disease. Neuro Endocrinol Lett; 2005 Dec;26(6):699-703
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of the insulin-like growth factor I gene promoter (P1) polymorphism in thyroid nodular disease.
  • OBJECTIVES: Due to the recent increase of incidence of thyroid nodules and the known risk of malignant transformation, there is an elevated risk of thyroid cancer in Poland.
  • Although the IGF-I system in thyroid cancer has been studied, little is known about the gene and its promoter structure changes.
  • Our aim was to assess, whether the analysis of the IGF-I gene promoter region and 5'UTR exon 1 structure may be useful in assessing the risk of thyroid carcinoma.
  • MATERIAL: Our study included 46 patients that underwent strumectomy due to a presence of thyroid nodules.
  • METHODS: All patients underwent clinical examination and laboratory investigations to assess their thyroid structure and function.
  • In our study we revealed no significant difference between carcinomatous and non-carcinomatous groups of patients in terms of presence of nucleotide change, but Fisher's exact test gave a significant result in terms of the efficacy of detecting follicular adenoma.
  • Moreover, the patients with nucleotide change had thyroid glands significantly smaller in volume.
  • CONCLUSIONS: We conclude that the molecular analysis of the IGF-I gene promoter is thought to be of a functional significance, but probably could not be considered useful in the assessment of risk of thyroid cancer in thyroid nodules.
  • [MeSH-major] Adenoma / diagnosis. Biomarkers, Tumor / genetics. Carcinoma / diagnosis. Goiter / genetics. Insulin-Like Growth Factor I / genetics. Thyroid Nodule / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16380677.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


79. Yusim A, Aspelund G, Ahrens W, Martel M, Scoutt LM, Donovan PI, Udelsman R: Intrathyroidal parathyroid adenoma. Thyroid; 2006 Jun;16(6):619-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrathyroidal parathyroid adenoma.
  • [MeSH-major] Adenoma / diagnosis. Parathyroid Neoplasms / diagnosis. Thyroid Gland / pathology
  • [MeSH-minor] Female. Humans. Hyperparathyroidism / diagnosis. Hyperparathyroidism / pathology. Magnetic Resonance Imaging / methods. Middle Aged. Parathyroid Hormone / blood. Radiopharmaceuticals. Technetium Tc 99m Sestamibi

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16839266.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


80. Liu FH, Hsueh C, Chang HY, Liou MJ, Huang BY, Lin JD: Sonography and fine-needle aspiration biopsy in the diagnosis of benign versus malignant nodules in patients with autoimmune thyroiditis. J Clin Ultrasound; 2009 Nov-Dec;37(9):487-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonography and fine-needle aspiration biopsy in the diagnosis of benign versus malignant nodules in patients with autoimmune thyroiditis.
  • PURPOSE: To correlate sonographic (US) characteristics and results of fine-needle aspiration biopsy (FNAB) of thyroid nodules in autoimmune thyroiditis (AT) with surgical pathological findings.
  • RESULT: Twenty-four of the 40 nodules were malignant, including 20 papillary carcinomas, 3 follicular carcinomas, and 1 medullary carcinoma.
  • Of the 16 benign nodules, 8 were nodular hyperplasia, 6 lymphocytic thyroiditis, and 1 each follicular adenoma and Hürthle cell adenoma.
  • The only US parameter that was significant in malignant vs. benign nodules was the presence of poorly defined margins.
  • Based on preoperative cytology, 22 of the 23 malignant nodules were correctly diagnosed, and 10 of the 14 benign nodules were correctly identified.
  • CONCLUSION: No single US parameter can predict thyroid malignancy in patients with AT.
  • [MeSH-major] Biopsy, Fine-Needle. Neoplasms / surgery. Neoplasms / ultrasonography. Thyroid Neoplasms / surgery. Thyroid Neoplasms / ultrasonography. Thyroiditis, Autoimmune / surgery. Thyroiditis, Autoimmune / ultrasonography

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley Periodicals, Inc. J Clin Ultrasound, 2009.
  • (PMID = 19750546.001).
  • [ISSN] 1097-0096
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Pérez-Ruiz L, Ros-López S, Gudelis M, Latasa-Gimeno JA, Artigas-Marco C, Pelayo-Salas A: Isthmectomy: a conservative operation for solitary nodule of the thyroid isthmus. Acta Chir Belg; 2008 Nov-Dec;108(6):699-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isthmectomy: a conservative operation for solitary nodule of the thyroid isthmus.
  • In 31 patients, lesions were limited to the thyroid isthmus with evidence of benign or undetermined pathology on ultrasound-guided fine-needle aspiration biopsy.
  • RESULTS: Preoperatively, thyroid nodules on ultrasonography were solid in 26 patients and mixed with cystic and solid components in 2.
  • Histological examination showed nodular hyperplasia in 29 cases, follicular adenoma in 1 and papillary thyroid carcinoma in 1.
  • Ultrasonographic scanning revealed thyroid nodules in 17 patients, in 16 of which nodules range from one to five (0.5 to 2 cm in size) and further surgery was not indicated.
  • The detection of recurrent nodules was independent of the time elapsed since thyroid isthmectomy.
  • CONCLUSIONS: These findings document the feasibility and efficacy of isthmectomy in solitary thyroid nodules confined to the isthmus.
  • [MeSH-major] Thyroid Nodule / surgery. Thyroidectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241921.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


82. Jogai S, Al-Jassar A, Temmim L, Dey P, Adesina AO, Amanguno HG: Fine needle aspiration cytology of the thyroid: a cytohistologic study with evaluation of discordant cases. Acta Cytol; 2005 Sep-Oct;49(5):483-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of the thyroid: a cytohistologic study with evaluation of discordant cases.
  • OBJECTIVE: To analyze the diagnostic efficacy of fine needle aspiration cytology (FNAC) in the initial evaluation of thyroid nodules, with special emphasis on discrepant cytologic diagnoses.
  • STUDY DESIGN: A total of 192 thyroid fine needle aspirates with subsequent histopathologic follow-up were analyzed.
  • The cytologic diagnoses were divided into 4 categories: positive for malignancy, negative for malignancy, indeterminate for diagnosis and nondiagnostic.
  • The majority of these were "follicular neoplasms."
  • A false positive diagnosis was made in 1 case (0.5%), proven a follicular adenoma on histopathologic examination.
  • A false negative diagnosis was seen in 3.6% of cases.
  • CONCLUSION: FNAC is a safe, sensitive and specific technique in the initial evaluation of thyroid nodules.
  • A correct cytologic diagnosis can be achieved in a majority of cases, thus obviating the need for a second surgical intervention.
  • [MeSH-major] Diagnostic Errors / prevention & control. Epithelial Cells / pathology. Thyroid Gland / pathology. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Adult. Aged. Biopsy, Fine-Needle / standards. Diagnosis, Differential. False Negative Reactions. False Positive Reactions. Female. Humans. Male. Middle Aged. Observer Variation. Predictive Value of Tests. Reproducibility of Results. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334023.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Boguszewski CL, Bianchet LC, Raskin S, Nomura LM, Borba LA, Cavalcanti TC: Application of genetic testing to define the surgical approach in a sporadic case of multiple endocrine neoplasia type 1. Arq Bras Endocrinol Metabol; 2010 Nov;54(8):705-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parathyroid scintigraphy showed tracer uptake in the inferior region of the left thyroid lobe, and cervical ultrasound showed a heterogeneous nodule in the same area, suggestive of a parathyroid adenoma (PA).
  • Genetic testing detected mutation in the MEN 1 gene and total parathyroidectomy with the implantation of a fragment of one gland in the forearm was performed.
  • Pathology showed a PA and 3 normal parathyroid glands, without hyperplasia, despite the diagnosis of MEN 1.
  • [MeSH-major] Adenoma / genetics. Genetic Testing / standards. Hyperparathyroidism, Primary / genetics. Multiple Endocrine Neoplasia Type 1 / genetics. Parathyroid Neoplasms / genetics


84. Albores-Saavedra J, Wu J: The many faces and mimics of papillary thyroid carcinoma. Endocr Pathol; 2006;17(1):1-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The many faces and mimics of papillary thyroid carcinoma.
  • This article provides an overview of the 15 histologic variants of papillary thyroid carcinoma listed by the 2004 World Health Organization (WHO) monograph on endocrine tumors.
  • The histologic features, differential diagnosis, and clinical course of each variant are discussed in some detail.
  • The follicular variants (conventional and macrofollicular) constitute a morphologic challenge because the majority of these tumors are encapsulated and, also, because, in many tumors, not all neoplastic cells show the nuclear features considered to be diagnostic of papillary carcinoma.
  • Moreover, hyperplastic thyroid lesions, follicular adenomas, and Hashimoto's thyroiditis may contain cells with clear nuclei resembling those of papillary carcinoma.
  • The WHO monograph defines papillary carcinoma with focal spindle and giant cell carcinoma components but its clinical behavior is unknown.
  • Papillary carcinoma with an insular pattern that does not show the artifactual separation of the cell nests has been misinterpreted as the solid variant of papillary carcinoma.
  • Papillary microcarcinomas include not only the conventional type and the follicular variants but also the tall cell and columnar cell variants.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenoma / diagnosis. Cell Nucleus / pathology. Diagnosis, Differential. Hashimoto Disease / diagnosis. Humans. Hyperplasia / diagnosis. Thyroid Gland / pathology. World Health Organization

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lab Invest. 1960 Jan-Feb;9:86-97 [14400378.001]
  • [Cites] Mod Pathol. 2000 Jul;13(7):742-6 [10912933.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):810-4 [7793479.001]
  • [Cites] Am J Clin Pathol. 1988 Feb;89(2):264-7 [3341287.001]
  • [Cites] Virchows Arch. 1996 Nov;429(4-5):213-9 [8972756.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):19-21 [11789725.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1336-40 [15371949.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):694-7 [16021577.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Dec;10(4):332-8 [12613443.001]
  • [Cites] Am J Clin Pathol. 1986 Jan;85(1):77-80 [3940424.001]
  • [Cites] Hum Pathol. 1995 Oct;26(10):1099-108 [7557943.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4578-80 [12881714.001]
  • [Cites] Pathol Int. 2002 Jan;52(1):54-8 [11940207.001]
  • [Cites] Hum Pathol. 1990 Nov;21(11):1151-5 [2227923.001]
  • [Cites] Histopathology. 1994 Dec;25(6):549-61 [7698732.001]
  • [Cites] Cancer. 1971 Sep;28(3):763-74 [5096937.001]
  • [Cites] Ann Diagn Pathol. 2003 Dec;7(6):348-53 [15018117.001]
  • [Cites] World J Surg. 1998 Jul;22(7):738-42; discussion 743 [9606291.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1110-6 [9305712.001]
  • [Cites] Diagn Cytopathol. 1998 Feb;18(2):93-7 [9484636.001]
  • [Cites] Am J Surg Pathol. 1988 Jan;12(1):22-7 [3337337.001]
  • [Cites] Cancer. 1994 Jan 15;73(2):416-23 [8293409.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):192-7 [8119720.001]
  • [Cites] Mod Pathol. 1999 Apr;12(4):400-11 [10229505.001]
  • [Cites] Virchows Arch. 1997 May;430(5):397-405 [9174630.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):740-53 [9477108.001]
  • [Cites] Endocr Pathol. 1997 Winter;8(4):283-292 [12114789.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):696-702 [11710686.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2637-41 [9703921.001]
  • [Cites] Am Surg. 1998 Apr;64(4):307-11 [9544139.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):878-82 [10690905.001]
  • [Cites] Mod Pathol. 1995 May;8(4):366-70 [7567932.001]
  • [Cites] Cleve Clin Q. 1976 WINTER;43(4):207-15 [1000814.001]
  • [Cites] Cancer. 1990 Mar 1;65(5):1173-9 [2302665.001]
  • [Cites] Am J Surg Pathol. 1989 Dec;13(12):1041-9 [2490923.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):964-74 [8712296.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):31-40 [12833452.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] Am J Surg Pathol. 1995 Oct;19(10):1209-15 [7573680.001]
  • [Cites] Semin Diagn Pathol. 1985 May;2(2):90-100 [3843693.001]
  • [Cites] J Clin Endocrinol Metab. 1948 Sep;8(9):749-61 [18880943.001]
  • [Cites] Am J Surg Pathol. 1985 Oct;9(10):705-22 [4061729.001]
  • [Cites] Endocr Pathol. 2002 Winter;13(4):301-11 [12665648.001]
  • [Cites] Hum Pathol. 1997 Jan;28(1):47-53 [9013831.001]
  • [Cites] Histopathology. 2004 Nov;45(5):493-500 [15500653.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):187-92 [6703194.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12):1485-92 [11717537.001]
  • [Cites] Histopathology. 2002 Oct;41(4):357-62 [12383219.001]
  • [Cites] Am J Surg Pathol. 1977 Jun;1(2):123-30 [602974.001]
  • [Cites] Endocr Pathol. 2004 Winter;15(4):297-305 [15681853.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12):1478-84 [11717536.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):625-7 [12697856.001]
  • [Cites] Virchows Arch. 2002 Apr;440(4):418-24 [11956824.001]
  • [Cites] Pathol Int. 1996 Dec;46(12):939-46 [9110345.001]
  • [Cites] Hum Pathol. 1991 Dec;22(12):1195-205 [1748427.001]
  • [Cites] Arch Pathol Lab Med. 1996 Apr;120(4):397-8 [8619755.001]
  • [Cites] Int J Surg Pathol. 2003 Oct;11(4):249-51 [14615819.001]
  • [Cites] Am J Surg Pathol. 1986 Oct;10(10):672-9 [3766846.001]
  • [Cites] Laryngoscope. 1997 Jan;107(1):95-100 [9001272.001]
  • [Cites] Acta Pathol Jpn. 1993 Jul-Aug;43(7-8):428-33 [8372687.001]
  • [Cites] Am J Surg Pathol. 1983 Dec;7(8):797-807 [6660352.001]
  • [Cites] Cancer. 1966 Aug;19(8):1039-52 [5916581.001]
  • (PMID = 16760576.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


85. Pennelli N, Pennelli G, Merante Boschin I, Pelizzo MR: Thyroid intrafollicular neoplasia (TIN) as a precursor of papillary microcarcinoma. Ann Ital Chir; 2005 May-Jun;76(3):219-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid intrafollicular neoplasia (TIN) as a precursor of papillary microcarcinoma.
  • BACKGROUND: The aim of this study was to identify a spectrum of morphological changes from benign reactive follicles to suspected thyroid intrafollicular neoplasia (TIN) and papillary microcarcinoma observed in different pathological processes of the thyroid gland.
  • CASE SERIES: In a retrospective study on a total of 105 cases, occult or incidental thyroid papillary microcarcinoma was found in association with multinodular goiter (52%), chronic thyroiditis (19%), follicular adenoma (19%), parathyroid neoplasia (5%), and no evident thyroid pathology (5%).
  • RESULTS: Atypical follicles are described in various pathological conditions correlating with lymphoid inflammatory infiltration, stromal sclerosis, and hyperplastic or neoplastic follicular nodules.
  • The histological pattern of papillary carcinoma is compared with morphological changes ranging from atrophic and/or reactive thyroid follicles, potential intrafollicular thyroid neoplasia (TIN) and papillary microcarcinoma.
  • CONCLUSIONS: The atypical features of follicular epithelial areas make up a wide spectrum that starts with the dispersion of nuclear chromatin.
  • Low- and high-grade TIN may represent a cytological marker of dysplastic lesions and precursors of thyroid papillary carcinoma when it is still in an early intrafollicular or pre-invasive stage in various pathological processes of the thyroid.
  • [MeSH-major] Carcinoma, Papillary / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16355851.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


86. Taniguchi K, Takano T, Miyauchi A, Koizumi K, Ito Y, Takamura Y, Ishitobi M, Miyoshi Y, Taguchi T, Tamaki Y, Kato K, Noguchi S: Differentiation of follicular thyroid adenoma from carcinoma by means of gene expression profiling with adapter-tagged competitive polymerase chain reaction. Oncology; 2005;69(5):428-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of follicular thyroid adenoma from carcinoma by means of gene expression profiling with adapter-tagged competitive polymerase chain reaction.
  • OBJECTIVE: Since preoperative differentiation between follicular thyroid adenoma (FTA) and carcinoma (FTC) remains very difficult, the purpose of this study was to identify the genes differentially expressed in FTA and FTC in order to construct a diagnostic system based on such genes for differentiation of FTA and FTC.
  • RESULTS: The diagnostic system for differentiation of FTA and FTC, constructed with the aid of the learning set samples, was based on 60 genes differentially expressed in FTA and FTC, which included several genes previously identified as overexpressed in FTC (DPP4, KRT19 and IGFBP3) or FTA (trefoil factor 3 and thyroid peroxidase).
  • [MeSH-major] Adenoma / diagnosis. Adenoma / genetics. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16319515.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 63231-63-0 / RNA
  •  go-up   go-down


87. Norman J, Politz D, Browarsky I: Diagnostic aspiration of parathyroid adenomas causes severe fibrosis complicating surgery and final histologic diagnosis. Thyroid; 2007 Dec;17(12):1251-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic aspiration of parathyroid adenomas causes severe fibrosis complicating surgery and final histologic diagnosis.
  • OBJECTIVE: To determine whether fine-needle aspiration (FNA) of parathyroid adenomas may cause a severe fibrotic reaction of the gland and surrounding structures, making surgery more difficult and histology more confusing.
  • DESIGN: A study was conducted over a 33-month period to compare the operative findings of 30 patients who underwent FNA of a parathyroid adenoma to those of 3000 patients who had not had their parathyroid tumor aspirated.
  • All aspirations were performed by referring physicians under direct ultrasound guidance within 3 months of surgery, and all adenomas were located in routine positions.
  • Patients who had previous thyroid or parathyroid surgery were not included.
  • CONCLUSIONS: FNA of parathyroid adenomas can cause a severe fibrotic process that typically involves adjacent tissues.
  • FNA of parathyroid adenomas should be avoided unless absolutely necessary.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / surgery. Biopsy, Fine-Needle / adverse effects. Parathyroid Neoplasms / diagnosis. Parathyroid Neoplasms / surgery
  • [MeSH-minor] Diagnosis, Differential. Fibrosis / diagnosis. Fibrosis / etiology. Fibrosis / pathology. Humans. Parathyroid Glands / pathology. Parathyroid Glands / surgery. Parathyroidectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Thyroid. 2008 May;18(5):581-2; author reply 583-4 [18466081.001]
  • (PMID = 17887929.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Ito Y, Yoshida H, Tomoda C, Miya A, Kobayashi K, Matsuzuka F, Kakudo K, Kuma K, Miyauchi A: HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma. Anticancer Res; 2005 Jan-Feb;25(1A):179-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma.
  • BACKGROUND: HBME-1 has been recognized as a useful marker for diagnosing thyroid carcinoma.
  • In this study, we investigated whether it has a diagnostic value for discriminating follicular carcinoma from adenoma.
  • MATERIALS AND METHODS: We investigated HBME-1 expression in 138 follicular carcinomas, 155 follicular adenomas, 98 adenomatous nodules and 37 papillary carcinomas, using anti-HBME-1 monoclonal antibody.
  • RESULTS: HBME-1 was positive in 60.9% of follicular carcinoma and the incidence was significantly higher (p<0.0001) than that of follicular adenoma, 30.3%.
  • In adenomatous nodules, only 17.3% were classified as positive, which was lower even than that of follicular adenoma (p=0.0257).
  • We calculated the positive predictive value of HBME-1 in discriminating follicular carcinoma from adenoma as 64.2%.
  • CONCLUSION: These results suggest that, although HBME-1 contributes to the diagnosis of papillary carcinoma, it could not be applied in the preoperative diagnosis of follicular carcinoma, for example, using fine-needle aspiration biopsy samples.
  • [MeSH-major] Adenocarcinoma, Follicular / metabolism. Adenoma / metabolism. Biomarkers, Tumor / biosynthesis. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816536.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HBME-1 antigen
  •  go-up   go-down


89. Iqbal CW, Wahoff DC: Diagnosis and management of pediatric endocrine neoplasms. Curr Opin Pediatr; 2009 Jun;21(3):379-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of pediatric endocrine neoplasms.
  • PURPOSE OF REVIEW: To guide the clinician in the diagnostic evaluation of endocrine neoplasms, to distinguish between benign and malignant and determine when surgical referral is indicated.
  • RECENT FINDINGS: Thyroid nodules are uncommon but malignant in as many as 27% of patients.
  • Fine needle aspiration should be considered in adolescents, in which accuracy is as high as 90%; surgical resection should be undertaken in all preadolescents (<13 years) with a thyroid nodule.
  • Prognosis for most primary thyroid malignancies is favorable.
  • Primary hyperparathyroidism is rare and due to an adenoma in up to 70% of patients.
  • Adrenal neoplasms cover a wide spectrum of disorder.
  • Malignant lesions of the adrenal gland carry a poor prognosis when complete surgical resection cannot be achieved.
  • [MeSH-major] Endocrine Gland Neoplasms
  • [MeSH-minor] Adolescent. Child. Combined Modality Therapy. Diagnosis, Differential. Humans. Morbidity. Prognosis. Survival Rate. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19421059.001).
  • [ISSN] 1531-698X
  • [Journal-full-title] Current opinion in pediatrics
  • [ISO-abbreviation] Curr. Opin. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 75
  •  go-up   go-down


90. Jing X, Michael CW, Pu RT: The clinical and diagnostic impact of using standard criteria of adequacy assessment and diagnostic terminology on thyroid nodule fine needle aspiration. Diagn Cytopathol; 2008 Mar;36(3):161-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical and diagnostic impact of using standard criteria of adequacy assessment and diagnostic terminology on thyroid nodule fine needle aspiration.
  • The study was aimed to investigate the impact of using standard criteria for assessing specimen adequacy and diagnostic terminology (CAST) on fine-needle aspiration (FNA) diagnosis and clinical management of thyroid nodules.
  • In comparison to group A, group B showed a significantly lower rate of nondiagnostic specimens (RND) (16.1% vs. 21.6%, P <or= 0.01) and rate of descriptive diagnoses (RDD) (3.8% vs. 14.5%, P <or= 0.001) and greater non-neoplastic (70.0% vs. 64.1%, P<0.05) and follicular cell lesions (7.4% vs. 4.3%, P<0.05) but a similar percentage of neoplastic diagnoses.
  • We concluded that use of the standard CAST on FNA diagnosis of thyroid nodules significantly reduced RND and RDD, providing more consistent diagnoses among the pathologists as well as better and more uniform communication between the pathologists and the clinicians.
  • [MeSH-major] Biopsy, Fine-Needle / standards. Specimen Handling / standards. Thyroid Gland / pathology. Thyroid Nodule / diagnosis
  • [MeSH-minor] Adenoma, Oxyphilic / diagnosis. Female. Hashimoto Disease / diagnosis. Humans. Male. Middle Aged. Reproducibility of Results. Terminology as Topic. Thyroid Neoplasms / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18231997.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Haddy N, Andriamboavonjy T, Paoletti C, Dondon MG, Mousannif A, Shamsaldin A, Doyon F, Labbé M, Robert C, Avril MF, Fragu P, Eschwege F, Chavaudra J, Schvartz C, Lefkopoulos D, Schlumberger M, Diallo I, de Vathaire F: Thyroid adenomas and carcinomas following radiotherapy for a hemangioma during infancy. Radiother Oncol; 2009 Nov;93(2):377-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid adenomas and carcinomas following radiotherapy for a hemangioma during infancy.
  • This paper presents the incidence of differentiated thyroid adenomas and carcinomas after radiotherapy in this cohort.
  • The radiation dose received by the thyroid during radiotherapy, estimated in 3497 of the 3795 patients using specific software, was 41 mGy on average.
  • Thyroid tumor cases were obtained by sending out a questionnaire, and were verified in pathological reports.
  • Estimates of thyroid cancer specific incidence rates in the French population were obtained from the French cancer registry network.
  • RESULTS: During an average follow-up of 35 years, 11 patients developed a differentiated thyroid carcinoma and 44 a thyroid adenoma.
  • The incidence of thyroid adenoma was found to be higher among taller and heavier individuals.
  • The incidence of both thyroid carcinoma and adenoma was higher among non-smoker patients.
  • A significant dose-response relationship was found between the radiation dose received by thyroid and the risk of thyroid cancer (Excess Relative Risk per GY, ERR/Gy: 14.7, 95%CI: 1.6-62.9) and of adenoma (ERR/Gy: 5.7, 95%CI: 0.7-19.4).
  • CONCLUSION: This study confirms that radiation treatment performed in the past for hemangioma during infancy increased the risk of thyroid carcinoma and adenoma.
  • Patients treated with external radiotherapy or with Radium 226 applicators for hemangiomas have to be more specifically followed up because this is the subgroup in whom the highest doses were received by the thyroid gland (more than 90% of the radiation doses were higher than 100 mGy).
  • They are therefore more at risk of developing thyroid cancer.
  • [MeSH-major] Hemangioma / radiotherapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Thyroid Neoplasms / etiology


92. Kim WJ, Souillard R, Brandwein MS, Lawson W, Som PM: Follicular adenoma in a juxtathyroidal thyroglossal duct cyst with papillary carcinoma in the adjacent thyroid gland. Am J Otolaryngol; 2005 Sep-Oct;26(5):348-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular adenoma in a juxtathyroidal thyroglossal duct cyst with papillary carcinoma in the adjacent thyroid gland.
  • This patient presented with a neck mass diagnosed as a papillary thyroid carcinoma by fine-needle aspiration.
  • After surgery, the initial diagnosis was papillary thyroid carcinoma.
  • After correlation with the computed tomography, the diagnosis was revised to a papillary thyroid carcinoma plus a follicular adenoma in a juxtathyroidal thyroglossal duct cyst.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma, Papillary / diagnosis. Thyroglossal Cyst / diagnosis. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16137536.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Jaffar R, Mohanty SK, Khan A, Fischer AH: Hemosiderin laden macrophages and hemosiderin within follicular cells distinguish benign follicular lesions from follicular neoplasms. Cytojournal; 2009;6:3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemosiderin laden macrophages and hemosiderin within follicular cells distinguish benign follicular lesions from follicular neoplasms.
  • BACKGROUND: Published criteria to distinguish benign colloid nodules from follicular neoplasms emphasize only three interdependent features: size of follicles, amount of colloid, and cellularity.
  • METHODS: This study quantified the significance of cystic change, defined as presence of macrophages, and the presence of hemosiderin in either the macrophages or follicular cells.
  • The cohort consisted of 165 patients with fine needle aspiration (FNA) and histologic follow-up of either goiter (101), follicular adenoma (47), or follicular carcinoma (17).
  • Papillary thyroid carcinomas and Hürthle cell neoplasms were excluded from the cohort, because these categories are known to show cystic change and hemosiderin.
  • RESULTS: Hemosiderin within macrophages were seen in 67% (68 of 101) of the goiters and only 6% (four of 64) of follicular neoplasms (P<.0001).
  • All four follicular neoplasms with hemosiderin in macrophages were adenomas.
  • Three of these four had equivocal features of a benign colloid nodule histologically.
  • None of the 17 follicular carcinomas had hemosiderin in macrophages (P<.12).
  • Macrophages without hemosiderin also strongly distinguished goiters from neoplasms (83% vs 17%) but appears less useful as a criterion since macrophages were present within 3 of 17 follicular carcinomas.
  • Hemosiderin within follicular epithelial cells was present in 18% (18 of 101) of goiters, whereas none of the 64 follicular neoplasms had intraepithelial hemosiderin (P<.0003).
  • CONCLUSIONS: If papillary thyroid carcinoma and Hürthle cell neoplasm are ruled out, our findings indicate that the presence of hemosiderin virtually excludes a clinically significant follicular neoplasm.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytojournal. 2008;5:6 [18394201.001]
  • [Cites] Diagn Cytopathol. 2007 Aug;35(8):525-8 [17636488.001]
  • [Cites] Cytopathology. 2007 Apr;18(2):105-11 [17397495.001]
  • [Cites] Cytopathology. 1999 Jun;10(3):171-9 [10390065.001]
  • [Cites] J Ultrasound Med. 2003 Oct;22(10):1083-90 [14606565.001]
  • [Cites] Acta Cytol. 1992 Mar-Apr;36(2):142-6 [1542996.001]
  • [Cites] Acta Cytol. 1989 Jan-Feb;33(1):53-60 [2916371.001]
  • [Cites] Cancer. 1986 Mar 15;57(6):1164-70 [3943039.001]
  • [Cites] Acta Cytol. 1990 May-Jun;34(3):345-51 [2343690.001]
  • [Cites] Mayo Clin Proc. 1994 Jan;69(1):44-9 [8271850.001]
  • (PMID = 19495407.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2678825
  • [Keywords] NOTNLM ; Benign colloid nodule / follicular cells / hemosiderin laden macrophages / hemosiderin within follicular neoplasms / macrophages
  •  go-up   go-down


94. Karges B, Krause G, Homoki J, Debatin KM, de Roux N, Karges W: TSH receptor mutation V509A causes familial hyperthyroidism by release of interhelical constraints between transmembrane helices TMH3 and TMH5. J Endocrinol; 2005 Aug;186(2):377-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations of the human thyrotrophin receptor (TSH-R) are a cause of thyroid adenomas and hyperthyroidism.
  • Here we study mechanisms of receptor activation in a genomic TSH-R variant V509A located in transmembrane helix (TMH) 3, which we identify in a family with congenital hyperthyroidism, multiple adenomas and follicular thyroid cancer.
  • In conclusion, we delineate a novel mechanism of constitutive TSH-R activation, leading to thyroid hyperfunction and neoplasia.
  • [MeSH-minor] Adenoma / genetics. Adolescent. Base Sequence. Carcinoma, Papillary, Follicular / genetics. Child, Preschool. Cyclic AMP / metabolism. DNA. Female. Genetic Predisposition to Disease. Goiter / genetics. Helix-Loop-Helix Motifs. Humans. Male. Middle Aged. Models, Molecular. Molecular Conformation. Molecular Sequence Data. Pedigree. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16079263.001).
  • [ISSN] 0022-0795
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Thyrotropin; 9007-49-2 / DNA; E0399OZS9N / Cyclic AMP
  •  go-up   go-down


95. Zhao J, Leonard C, Gemsenjäger E, Heitz PU, Moch H, Odermatt B: Differentiation of human follicular thyroid adenomas from carcinomas by gene expression profiling. Oncol Rep; 2008 Feb;19(2):329-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of human follicular thyroid adenomas from carcinomas by gene expression profiling.
  • It is difficult to distinguish benign from malignant follicular thyroid tumors by histological or cytological examination.
  • The goal of this study was to reveal gene expression variations between benign and malignant follicular lesions of the thyroid gland.
  • We investigated gene expression profiles from 24 follicular thyroid tumors (12 carcinomas and 12 adenomas) and 13 normal thyroid tissues using high-density human cDNA arrays.
  • The identification of gene expression changes was based on signal intensity ratios of tumor versus normal thyroid parenchyma.
  • Expression patterns of a set of known genes were found to be significantly different between follicular adenomas and follicular carcinomas.
  • Our results demonstrate a potential use of gene expression profiling for differentiating benign from malignant follicular thyroid tumors.
  • A detailed investigation of the differentially expressed genes could give new insights into molecular pathways of malignant transformation of thyroid follicular neoplasm and may help to develop a molecular tool for the preoperative differential diagnosis.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenoma / diagnosis. Gene Expression Profiling. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18202778.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


96. Wang SL, Wu MT, Yang SF, Chan HM, Chai CY: Computerized nuclear morphometry in thyroid follicular neoplasms. Pathol Int; 2005 Nov;55(11):703-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computerized nuclear morphometry in thyroid follicular neoplasms.
  • Differential diagnosis of follicular adenoma (FA) and follicular carcinoma (FC) of the thyroid can be challenging in the routine practice of surgical pathology because the diagnosis of FC is strictly defined and identification depends on the presence of invasion of the capsule or blood vessels.
  • The present study investigated the diagnostic role of objective computerized nuclear morphometry in follicular neoplasms.
  • Thirty-six cases of thyroid FC and 36 cases of FA from patients who were matched by age and sex were studied.
  • In conclusion, computerized nuclear morphometry can be considered a helpful ancillary tool for differential diagnosis of FA and FC.
  • [MeSH-major] Adenocarcinoma, Follicular / ultrastructure. Adenoma / ultrastructure. Cell Nucleus / ultrastructure. Thyroid Neoplasms / ultrastructure
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16271082.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


97. Blank W, Braun B: Sonography of the thyroid--Part 1. Ultraschall Med; 2007 Dec;28(6):554-68; quiz 570-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonography of the thyroid--Part 1.
  • [MeSH-major] Thyroid Diseases / ultrasonography. Thyroid Gland / ultrasonography
  • [MeSH-minor] Adenoma / radionuclide imaging. Adenoma / ultrasonography. Diagnosis, Differential. Humans. Organ Size. Reference Values. Sensitivity and Specificity. Thyroid Neoplasms / classification. Thyroid Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18074309.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng; ger
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


98. Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A: Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol; 2009;20(3):149-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.
  • Insulin-like growth factor mRNA binding protein 3 (IMP3) is an mRNA-binding protein that regulates transcription of insulin-like growth factor II affecting cell proliferation during embryogenesis.
  • The purpose of our study was to evaluate IMP3 expression in thyroid follicular lesions, to determine whether it has a role in differentiating among these lesions, and to understand their biological relationships.
  • We immunostained 219 thyroid lesions selected from our surgical pathology archives including 14 hyperplastic colloid nodules (CN), 19 Hashimoto's thyroiditis (HT), two Graves disease (GD), ten Hürthle cell adenoma (HCA), 20 follicular adenoma (FA), 37 conventional papillary thyroid carcinoma (PTC), 60 follicular variant of papillary carcinoma (FVPC), 19 Hürthle cell carcinoma (HCC), 32 follicular carcinoma (FC), and six poorly differentiated/anaplastic carcinoma.
  • In all cases, residual thyroid tissue, CN, HT, GD, HCA, and FA were completely negative for IMP3 staining.
  • No significant correlation was found between pathologic tumor characteristics and IMP3 expression in differentiated follicular pattern thyroid carcinoma.
  • With 100% specificity and 69% sensitivity for FC as compared to FA and 100% specificity for FVPC, again compared to FA, IMP3 has the potential to be diagnostically useful in differentiating malignant and benign follicular pattern thyroid lesions.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Biomarkers, Tumor / analysis. Neoplasm Proteins / biosynthesis. RNA-Binding Proteins / biosynthesis. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1994 Apr;7(3):295-300 [7520169.001]
  • [Cites] J Pathol. 2005 Jul;206(3):305-11 [15852498.001]
  • [Cites] Thyroid. 2001 Dec;11(12):1101-7 [12186496.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):305-17 [15947105.001]
  • [Cites] Am J Clin Pathol. 2003 Jul;120(1):71-7 [12866375.001]
  • [Cites] Am J Surg Pathol. 2008 Feb;32(2):304-15 [18223334.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1304-9 [9824112.001]
  • [Cites] Cancer. 2008 Feb 25;114(1):49-56 [18098206.001]
  • [Cites] World J Surg. 2000 Aug;24(8):913-22 [10865035.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] Hum Pathol. 2007 Aug;38(8):1178-83 [17521698.001]
  • [Cites] Pathology. 2005 Aug;37(4):296-8 [16194828.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):242-7 [17192788.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):143-50 [11789719.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):556-64 [16814207.001]
  • [Cites] Br J Cancer. 2003 Mar 24;88(6):887-94 [12644826.001]
  • [Cites] Oncogene. 1997 Jun 5;14(22):2729-33 [9178771.001]
  • [Cites] Mech Dev. 1999 Oct;88(1):95-9 [10525192.001]
  • [Cites] Int J Surg Pathol. 2005 Jul;13(3):235-8 [16086077.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):696-702 [11710686.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):256-64 [16082252.001]
  • [Cites] Exp Oncol. 2006 Mar;28(1):70-4 [16614712.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):882-7 [10955455.001]
  • [Cites] Am J Clin Pathol. 2006 Nov;126(5):700-8 [17050067.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 [16219715.001]
  • [Cites] Mod Pathol. 1995 Oct;8(8):870-2 [8552578.001]
  • [Cites] Acta Cytol. 2008 Mar-Apr;52(2):133-8 [18499984.001]
  • [Cites] Virchows Arch. 1998 May;432(5):427-32 [9645441.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2676-82 [18412154.001]
  • [Cites] Histopathology. 2004 Nov;45(5):493-500 [15500653.001]
  • [Cites] Endocr Pathol. 2005 Winter;16(4):295-309 [16627917.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):188-95 [15644775.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):699-701 [12618877.001]
  • [Cites] Pathol Res Pract. 2000;196(8):533-40 [10982016.001]
  • [Cites] Endocr Pathol. 2006 Summer;17(2):109-17 [17159243.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1101-10 [10190901.001]
  • (PMID = 19449140.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins
  •  go-up   go-down


99. Yang J, Schnadig V, Logrono R, Wasserman PG: Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer; 2007 Oct 25;111(5):306-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations.
  • BACKGROUND: The Papanicolaou Society of Cytopathology recently proposed 6 diagnostic categories for the classification of thyroid fine-needle aspiration (FNA) cytology.
  • METHODS: Patient cytology data were retrieved by a retrospective search of thyroid FNA in the institutional databases.
  • Cytologic diagnoses were classified as unsatisfactory, benign, atypical cellular lesion (ACL), follicular neoplasm (FN), suspicious for malignancy, and positive for malignancy.
  • RESULTS: Of 4703 FNA samples, 10.4% were classified as unsatisfactory, 64.6% were classified as benign, 3.2% were classified as ACL, 11.6% were classified as FN, 2.6% were classified as suspicious, and 7.6% were classified as malignant.
  • One thousand fifty-two patients had surgical follow-up, including 14.9% of patients with unsatisfactory FNA results, 9.8% of patients with benign results, 40.6% of patients with ACL results, 63.1% of patients with FN results, 86.1% of patients with suspicious results, and 79.3% of patients with malignant results.
  • Sources of errors included diagnoses on inadequate specimens, sample errors, and overlapping cytologic features between hyperplastic nodules and follicular adenoma.
  • The sensitivity and specificity of thyroid FNA for the diagnosis of malignancy were 94% and 98.5%, respectively.
  • CONCLUSIONS: The current results indicated that FNA provides an accurate diagnosis of thyroid malignancy.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma / pathology. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17680588.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Ito Y, Akinaga A, Yamanaka K, Nakagawa T, Kondo A, Dickson RB, Lin CY, Miyauchi A, Taniguchi N, Miyoshi E: Co-expression of matriptase and N-acetylglucosaminyltransferase V in thyroid cancer tissues--its possible role in prolonged stability in vivo by aberrant glycosylation. Glycobiology; 2006 May;16(5):368-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-expression of matriptase and N-acetylglucosaminyltransferase V in thyroid cancer tissues--its possible role in prolonged stability in vivo by aberrant glycosylation.
  • In this study, we report on an investigation of the expression of GnT-V and matriptase in thyroid neoplasm tissues to determine the clinical significance on the co-expression of these two proteins in thyroid cancer.
  • Although neither GnT-V nor matriptase was expressed in normal thyroid tissue, positive staining for matriptase and GnT-V was observed in 52/68 and 66/68 cases of papillary carcinoma, 3/23 and 10/23 cases of follicular carcinoma, 5/13 and 9/13 cases of follicular adenoma, and 11/28 and 6/28 cases of anaplastic carcinoma, respectively.
  • In contrast, the prognosis of thyroid carcinoma after surgery was neither correlated with the expression GnT-V nor matriptase, because the levels of their expression were quite low in anaplastic (undifferentiated) carcinomas.
  • [MeSH-major] N-Acetylglucosaminyltransferases / metabolism. Serine Endopeptidases / metabolism. Thyroid Neoplasms / classification. Thyroid Neoplasms / enzymology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16464868.001).
  • [ISSN] 0959-6658
  • [Journal-full-title] Glycobiology
  • [ISO-abbreviation] Glycobiology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA096851
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.4.1.- / N-Acetylglucosaminyltransferases; EC 2.4.1.155 / alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / matriptase
  •  go-up   go-down






Advertisement